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 Cystic fibrosis (CF) is a genetic disorder that affects 30,000 people in the United 
States and currently has no cure. Although CF affects all of the body’s systems, it is 
largely characterized as a lung disease. CF is characterized by a mutation in both copies 
of the gene for cystic fibrosis transmembrane conductance regulator (CFTR). A mutation 
in the CFTR gene leads to improper movement of chloride ions and water into the 
airways, which dysregulates the airway surface liquid volume and composition. 
Individuals with CF are prone to lung infections due to inefficient bacterial clearance and 
by the age of 18, eighty percent of patients with CF harbor Pseudomonas aeruginosa, 
with it being the most prevalent respiratory microorganism at that age. 
 P. aeruginosa is a gram negative, opportunistic bacterium that is found all over 
the planet. It is a serious threat to people with CF due to its ability to form large colonies 
 
 
 
 
known as mucoid pseudomonas. The mucoid strain of P. aeruginosa provides increased 
resistance to not only antibiotics but also opsonization and phagocytosis. Even if P. 
aeruginosa infection can be managed there is a delicate balance between controlling the 
infection and causing exacerbated neutrophilia and tissue damage due to increased 
inflammation. Many factors can affect the balance of the immune system including 
environmental toxicants such as arsenic. 
 Arsenic exposure is a health risk to many people worldwide through contaminated 
drinking water. Arsenic is able to leech out of granite and other sediments into 
groundwater and subsequently become included in drinking water. Arsenic has been 
shown to affect the immune response to pathogens, which can potentially lead to 
increased P. aeruginosa infection and is therefore a complication in people suffering 
from CF. 
 It is important to research the effects of CF, P. aeruginosa, and arsenic to 
understand how they are modulation the immune system and to potentially discover novel 
therapies to combat CF and bacterial infection. The Kim lab recently completed RNA 
sequencing analysis to measure the dysregulation of genes in response to these factors in 
zebrafish embryos. To understand how the immune system is being modulated by these 
factors the role of non-coding RNAs (ncRNA) were investigated. ncRNA have remained 
largely uncharacterized and, until recently, were thought to serve little to no purpose in 
our genome. Recent studies have shown ncRNA to be involved in many important 
biological processes such as embryonic development, transcriptional regulation, 
apoptosis, and immunity. The Kim lab is particularly interested in the role of micro-
RNAs (miRNA) and long intergenic non-coding RNAs (lincRNAs).  
 
 
 
 
 In order to better understand and characterize ncRNAs it is critical to study their 
mechanisms in vivo. The zebrafish (Danio rerio) is regarded as an excellent research 
model, because of the ease with which it can be genetically manipulated, the availability 
of transgenic lines, and its sole reliance on the innate immune system during the first 4-6 
weeks of development. In addition, the zebrafish’s optical clarity allows for the use of 
fluorescently-labeled bacterial strains to track and image infection in live zebrafish 
embryos. With the use of the zebrafish and high-throughput sequencing, the lab aims to 
aid in the discovery of novel therapies for people suffering from cystic fibrosis and 
bacterial infection. 
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CHAPTER 1 
INTRODUCTION 
1.1 Cystic fibrosis  
 Cystic fibrosis (CF) is the most common genetic disease among the Caucasian 
population, yet still remains an orphan disease. CF affects over 30,000 individuals in the 
United States alone with another 40,000 worldwide. Although CF is rare it is 
hypothesized that one in every 31 Americans is a carrier of the disease, which means that 
they are asymptomatic but are able to pass it on to their children (1). 
 1.1.1. History 
 CF was not characterized until 1938 when Dr. Dorothy Anderson noticed cysts 
and fibrosis in the pancreas of patients, which differentiated CF from other 
gastrointestinal disorders (2). The cause of CF remained elusive until the summer of 
1949, when it was discovered that several heat stroke patients had higher than normal 
concentrations of salt on their skin. It was therefore postulated that these individuals were 
suffering from severe dehydration and were failing to retain salt as well as healthy 
individuals (3). Since this discovery, physicians have been able to diagnose CF from 
infancy based on skin salt concentrations that exceed 60 mM. 
 In 1989 the gene responsible for CF was cloned and discovered by Dr. Lap-Chee 
Tsui and his team and identified as the cystic fibrosis transmembrane conductance 
regulator (CFTR) (4). The CFTR gene is located on the long arm of  human chromosome 
7, region q31-q32 and its gene codes for the 1,480 amino acid CFTR protein (5). The 
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CFTR protein is a large glycoprotein and consists of two-membrane spanning regions 
along with a cytoplasmic regulatory R domain. The CFTR protein is a cAMP-regulated 
chloride ion channel important in chloride conductance and the regulation of salt 
secretion from most epithelial cells. In healthy individuals CFTR secretions are thin and 
watery, but with the CFTR mutation they become much thicker. The thickness is due to 
the retention of water by the epithelial cells due to improper transport of chloride ions (1, 
6). 
 As of today there are almost 2,000 recorded mutations of the CFTR gene, but over 
70% of CF cases are due to a single amino acid deletion spanning positions 507 and 508 
in the CFTR gene. This mutation ultimately results in the removal of a single codon of 
phenylalanine (F), which is termed p.Phe508del (also known as ΔF508 or F508del) (7). 
This deletion causes the CFTR protein to become misfolded during translation resulting 
in the partial degradation of the protein soon after generation (8). The remaining portion 
of the protein traffics to the cell membrane yet has reduced efficiency and function. In 
addition, the deletion of phenylalanine leads to a change in the coding for isoleucine at 
codon 507 resulting in a change from ATC to ATT. This in turn causes a structural 
change that reduces translation efficiency. In other CFTR mutations the protein may 
range from poorly regulated to completely dysfunctional, expression at lower 
concentrations than normal, reduced chloride conductance, poor channel gating, or the 
transcript may be unable to be translated. These dysfunctions are brought about by a 
variety of ways including: single amino acid substitutions, altered RNA processing, 
affected promoter regions, or large rearrangements of the gene. Whether it is a rare or 
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common mutation, when an individual has a defective CFTR gene in both alleles they 
will inevitably display a classic group of CF characteristics (1, 7). 
 
Figure 1.1. Clinical manifestations of cystic fibrosis. Cystic fibrosis is a 
multi-organ disease that is generally diagnosed during infancy with an 
elevated sweat chloride concentrated above 60 mM. The degree of organ 
dysfunction varies considerably depending on genetic factors, age, airway 
obstruction, and infection with Pseudomonas aeruginosa. The significance 
of dysfunction in each individual organ will determine the degree and/or 
presence of its associated disorders. Adapted from Cutting, G. R. (2015). 
"Cystic fibrosis genetics: from molecular understanding to clinical 
application." Nature Reviews Genetics 16(1): 45-56. 
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 1.1.2 Manifestations of cystic fibrosis 
  1.1.2.1. General pathology 
 Due to the near ubiquity of CFTR protein in all cells, CF is a multisystem disease 
with far reaching complications. As a result of the progress made in CF therapeutics, the 
predicted life span of individuals with CF has risen from about 1 year in the early 1950s 
to 37 years today (9, 10). As the average CF patient life span has increased, many of the 
less problematic complications of CF have become increasingly troublesome with age. 
  Complications like cystic fibrosis bone disease (CFBD) have become more 
prevalent. CFBD is brought about by decreased absorption of vitamin D and vitamin K 
due to a combination of many factors. Pancreatic fibrosis and failure, in combination with 
the prevalence of inflammatory cytokines, results in malnutrition and poor growth and 
therefore lowered bone density. In addition, the use of glucocorticoid steroids to control 
lung infection and inflammation has led to poor bone density, which results in poor 
growth. This leads to a conundrum in which it is important to control lung infection but 
the treatments have negative effects later in the patient’s life (11-13). 
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Figure 1.2. Symptoms of cystic fibrosis leading to low bone density and 
cystic fibrosis bone disease (CFBD). A web of complications are known to 
exacerbate related symptoms and lead to low bone density. Adapted from 
Aris, R. M., P. A. Merkel, L. K. Bachrach, et al., (2005). "Guide to Bone 
Health and Disease in Cystic Fibrosis." The Journal of Clinical 
Endocrinology & Metabolism 90(3): 1888-1896. 
 As mentioned above, the pancreas is also affected by cystic fibrosis. From an 
early age, CFTR malfunction results in decreased transport of chloride and bicarbonate 
into the pancreatic ducts. This in turn causes high concentration of proteins to be secreted 
by the acinar cells. These reduced pancreatic secretions with high protein concentration 
lead to obstruction of ducts by mucous and debris, destruction of acini, and fibrosis. The 
fibrosis and malfunction of the pancreas over the life of the patient leads to decreased 
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conversion of food into energy and the regulation of blood sugar. This malfunction can 
cause malnutrition in the patient’s early life and later in life lead to an almost complete 
inability to absorb fat soluble vitamins and carbohydrates. CF can eventually cause 
diabetes via progressively reduced levels of insulin and glucagon (14, 15). 
 Another major effect of CF is gastrointestinal comorbidity and complications. 
CFTR is exceedingly important in digestion through hydration of the mucosal lining of 
epithelial cells via secretion of water into the intestines. Therefore, when CF is present it 
can cause meconium ileus or bowel obstruction along with obstruction of the small 
intestine, which is a persistent problem for people suffering from CF. In fact, about 10-
15% of infants with CF will die due to bowel obstruction. Recent clinical trials show that 
even with physician intervention, delayed hospital arrival following the rise of symptoms 
significantly increases morbidity (16). In addition, diseases such as celiac disease, 
Crohn’s disease, giardiasis, and lactose intolerance are common in CF patients (3). 
 Although there are many nutritional deficiencies that result from pancreatic 
damage and gastrointestinal complications, most can be controlled through strict diets 
and targeted therapies. Iron deficiency (ID), however, has been very difficult to remedy 
and is believed to be multifaceted (17-19). ID has been long documented as an issue in 
33% of pediatric CF cases and greater than 60% of adult CF cases. Interestingly, the use 
of iron supplements improved hypoferremia, but was unable to reverse anemia in adults 
with CF (20). Furthermore, in pediatric cases ID is common in healthy individuals that 
are properly nourished, but iron levels seem to increase with age and be positively 
correlated with inflammation rather than iron status (21). This suggests that something 
other than direct levels of iron must be the result of ID. Research has shown that the high 
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prevalence of ID is directly correlated with the severity of the level of lung disease in CF 
patients. The main factor leading to ID from lung disease is the presence of P. 
aeruginosa. Through the use of iron sequestering chemical compounds called 
siderophores, P. aeruginosa is able to sequester iron from its environment, supporting 
growth and proliferation. These siderophores obtain extracellular iron from the host and 
aid in the depletion of unbound iron in the host (18). In addition, it was found that ID is 
not only correlated with decreased lung function in patients with deteriorating health, but 
also correlated with the overall health of the patients and higher iron levels in the sputum 
(22). Overall, P. aeruginosa is responsible for ID, which is strongly associated with 
deteriorating health in patients with CF. 
  1.1.2.2. Respiratory pathology 
 Although CF is a multi-system disorder it is most commonly known as a lung 
disease, due to the overwhelming morbidity and mortality stemming from symptoms 
associated with CF lung disease. Roughly 80-90% of CF patients will ultimately succumb 
to respiratory failure as a result of defective CFTR protein (1, 23) As previously stated 
CFTR mutation causes a decrease in the hydration of the lung airway surface layer, 
causing thick mucus without salts. The thick mucus inevitably leads to impacted alveolar 
ducts which decreases lung function and airway dehydration. Although the use of 
therapeutic drugs such as corticoid steroids and mucus thinners have side effects, they 
have proved useful in aiding in the clearance of mucus and improving lung function. In 
addition, manual physical therapy and breathing techniques can be effective in aiding 
mucus clearance. This can be brought about though physical exercises and positioning or 
breathing in specific ways to loosen mucus (24, 25). Although physical and/or drug 
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therapies can be useful for increasing lung function, it is almost inevitable that successive 
bacterial lung infection will cause a tipping point which tragically cannot yet be 
overcome by modern medicine.  
   1.1.2.2.1. Respiratory bacterial infections 
 Chronic bacterial infections in CF patients are an unavoidable complication due to 
the modulation of the immune system resulting from CFTR mutation. The CF lung is the 
only area of the body that is exceptionally vulnerable to infections in CF patients. The 
urinary tract and skin, which are common areas of infection in healthy individuals, are 
not more vulnerable in CF patients. In healthy individuals when bacteria are inhaled the 
lungs will clear the pathogens without invoking a significant immune response, but the 
lungs of CF patients generate an excessive inflammatory response. People living with CF 
are unable to clear these infections easily and therefore the bacteria are able to replicate 
unhindered and establish chronic infections. Although the advent of antibiotics has 
significantly improved the life expectancy of patients with CF and is initially effective at 
reducing infections, antibiotics have added selective pressures which have resulted in 
antibiotic resistant strains of bacteria. Furthermore, many antibiotics like inhaled 
tobramycin are being disputed for their effectiveness and have resulted in controversy 
(26-28).  
 From childhood, bacterial colonization in CF individuals is apparent and these 
infections become chronic due to the host’s inability to properly eliminate the infection. 
Although the nature of specific infections varies depending on the age of the patient, 
bacterial colonies are always present. Staphylococcus aureus and Haemophilus influenzae 
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are the most common infections reoccurring from early childhood through adolescence. 
These infections are commonly treated and managed with antibiotics (19, 27, 29).  
 Burkholderia cepacia is a complex of opportunistic pathogens comprising seven 
genotypically distinct species (B. cepacia genomovars I-VII) that are of concern to CF 
patients. B. cepacia has the ability to penetrate the thick mucus layers of the CF lung and 
infect the epithelial cells that are typically difficult to contact. Individuals who have 
reached the stage of CF lung disease that necessitates a lung transplant are also at higher 
risk of mortality following transplantation when infected with B. cepacia genomovar III 
pre-operation. This statistic has led many transplant centers to disallow CF patients from 
their transplant lists if they are colonized with B. cepacia (30-32). Moreover, B. 
cenocepacia may be utilizing macrophages and the innate immune system to multiply 
and increase mortality through the development of a fatal, pro-inflammatory response 
mediated by Il-1signaling (33). 
  Similarly to B. cepacia, Stenotrophomonas maltophilia has also been increasing 
in prevalence in CF patients over the past few decades. S. maltophilia densities increase 
with patient age and correlate with antibiotic exposure. The rates of S. maltophilia 
occurrence have been cited to be from 4-30% in CF patients. Broad-spectrum antibiotic 
treatments and selective pressure are believed to be the drivers behind the increasing 
incidence of S. maltophilia in CF patients (2, 34, 35). Like B. cepacia, chronic S. 
maltophilia, is also responsible for an increased risk of death or lung transplant in 
individuals with CF (32). 
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 Pathogens are known to infect individuals with CF, but the most common 
infection involves the opportunistic pathogen, Pseudomonas aeruginosa. P. aeruginosa 
has been known to be the most important pathogen to infect CF patients since infections 
were described in the CF literature. P. aeruginosa is responsible for about 80% of the 
chronic respiratory infections in CF patients due to myriad factors including its resilience 
to antibiotic clearance (1, 36).  
1.2. Pseudomonas aeruginosa 
 Pseudomonas aeruginosa is a gram negative rod and an opportunistic pathogen in 
humans. P. aeruginosa is found in both plants and animals and due to its ability to live on 
many different sources of carbon, it is found all over the world in every environment 
humans inhabit. In healthy individuals P. aeruginosa infiltration rarely results in 
infection and is cleared without the initiation of a significant immune response. P. 
aeruginosa is also a common nosocomial infection representing roughly 10% of all 
nosocomial infections, is almost always associated with compromised immunity. P. 
aeruginosa owes this high pathogenicity to its effective virulence factors, such as drug 
pumps and other antibiotic-combating proteins. In addition, the cell membrane of P. 
aeruginosa is capable of blocking many drug targets (37).  Furthermore, P. aeruginosa is 
very effective at forming biofilms on medical devices such as ventilators and catheters, 
rendering them even more resistant to antimicrobials and providing them with a direct 
route for infection. In fact, pathogens like P. aeruginosa have prompted hospitals to 
implement continence training in elderly patients and intermittent catheterization in 
patients with spinal cord injury (38). Also, this growing health concern has prompted the 
use of polymers and other compounds to coat instruments and surfaces to combat the 
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arms race between antibiotics and antimicrobial resistance (39). Taken together, these 
factors make P. aeruginosa a potentially dangerous microorganism, especially in 
hospitals where there are likely to be greater numbers of immunocompromised patients. 
 1.2.1 P. aeruginosa infection and cystic fibrosis 
 Due to the reduction of water transport in the lungs, the airways become 
dehydrated in CF patients. CFTR dysfunction leads to a lack of transport of chloride and 
water causing a dehydrated airway epithelium and obstructed mucociliary clearance. This 
in turn makes the airway a good environment for bacterial infection by Staphylococcus 
aureus or Pseudomonas aeruginosa. When healthy individuals inhale microorganisms, 
these generally get stuck in the mucosal lining of the lung epithelial cells and are unable 
to penetrate the mucous. In addition, the mucus is moved out of the lungs via the 
mucociliary elevator, which is normally very effective at keeping the lungs a largely 
sterile environment (2). 
 P. aeruginosa is the most prevalent microorganism in individuals with CF with at 
least 85% of CF patients harboring the pathogen. This is important because over 90% of 
CF patients succumb to respiratory failure (6, 40). Although standard methods for 
treating bacterial infection can be effective, P. aeruginosa frequently mutates into a 
mucoid form with abundant alginate and PsI exopolysaccharide production, resulting in 
increased resistance, not only antibiotics, but also to opsonization and phagocytosis (41, 
42). This in turn causes an intense immune reaction yielding increased chemokine and 
cytokine expression and polymorphonuclear leukocyte (PMN) migration. In addition, 
serine proteases are released, causing increased inflammation and a self-perpetuating 
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cycle of lung damage. This increased inflammation does not correlate with decreased 
bacterial burden (43, 44). The obstruction of the airways eventually leads to decreased 
lung function, which is why most individuals with CF die prematurely from lung-related 
problems. 
 1.2.2. Virulence factors 
 Some strains of P. aeruginosa have over 15 genes coding for virulence factors, 
including genes that act to enable formation of biofilms, inhibit cytochrome C, and 
sequester iron. The roles of virulence factors in infection, and particularly infection in CF 
patients, have been studied extensively in an effort to understand why P. aeruginosa is so 
deadly to individuals with CF. There is no single virulence factor that can be targeted to 
remedy infection, but a collection of factors promote chronic P. aeruginosa infection 
(45). 
Quorum sensing (QS) is part of a multicomponent communication and regulatory 
network that is necessary for the production of virulence factors in P. aeruginosa 
populations. QS was first observed in Vibrio fischeri where bioluminescence is dependent 
on population density. P. aeruginosa’s QS network involves two independent QS 
systems, LasIR and RHIIR (45). Biofilm formation is also a result of QS, which begins 
when signal molecules 3-oxo-C12-homoserine lactone (HLS) and C4-HLS reach high 
enough concentrations to trigger Las and Rhl transcription factors as a result of high 
bacterial densities. Once Las and Rhl are triggered and activated a signaling cascade 
ultimately results in the formation of P. aeruginosa biofilms (46-49). 
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  Moreover, it has been proposed that even though QS is a pivotal player in the 
initial stages of infection and biofilm formation, its role may be less important over the 
duration of the infection (50). Indeed QS is important initially, with recent results 
showing that blocking pyocyanin and biofilm formation protects Caenorhabditis elegans 
and human lung epithelial cells from death caused by P. aeruginosa (51). Later in the 
timeline of chronic infection QS appears to become less important in that P. aeruginosa 
isolates from 166 CF patients were LasR mutants. This study suggests that LasR 
mutations may even be selected-for and correlated with the severity of lung disease (52). 
Furthermore, a study that analyzed 36 P. aeruginosa lineages found that there was 
convergent molecular evolution in 52 genes, suggesting that mutation and remodeling of 
regulatory networks have a role in adapting to the host and the selective pressures on P. 
aeruginosa (53). Interestingly, it has been proposed that QS mutants, given the moniker 
“cheating bacteria”, may utilize the functional QS systems of other members of the 
population as long as a balance is maintained (54-57). Taken together, it is apparent that 
the QS system is essential for early biofilm formation of P. aeruginosa, but becomes less 
vital to chronic infection as it adapts to selective pressures form the host.  
  1.2.2.1. Secretion systems 
 P. aeruginosa has distinct secretion systems that based upon their substrates have 
a spectrum of functions (58). Type I secretion system (T1SS) and type II secretion system 
(T2SS) transport various molecules through the inner and outer membranes of the 
bacteria to the outside the cell (59, 60). The type III secretion system (T3SS) acts as a 
molecular syringe to secrete effector proteins directly into the eukaryotic cell from the 
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bacterial cell (60, 61). These three systems act to release virulence factors and thereby aid 
in the pathogenicity of P. aeruginosa. 
 T1SS in P. aeruginosa mainly involves the function of alkaline metalloproteases 
(aprA) to degrade complement and cause hydrolysis of fibrin. T2SS virulence factors 
include: elastases (lasA and lasB), proteases (prpIL), and lipases (plcB), which, in 
combination with aprA, play a critical role in P. aeruginosa pathogenesis (62).  Although 
these virulence factors have long been known to act in a plethora of ways on a variety of 
targets, they are all important components of P. aeruginosa pathogenesis (63, 64). In 
addition, these factors have also all been implicated in lung disease and CF (65-67). 
Furthermore, these virulence factors are regulated by the QS system through transcription 
factors Las and Rhl (47, 49, 68). 
 The T2SS also secretes the most toxic of the P. aeruginosa virulence factors: 
Exotoxin A (toxA). toxA is regulated by QS and is a member of the mono-ADP-
ribosyltransferase family, which inactivates eukaryotic elongation factor 2 (eEF-2) by 
adding an additional ADP-ribose moiety to eEF-2 in a reaction called ADP-ribosylation 
(69, 70). Without eEF-2 the epithelial cells will necrotize from the lack of protein 
synthesis (71, 72). toxA has been shown to adapt both structurally and functionally 
during the course of infection to retain the pathogenicity of P. aeruginosa (53). toxA has 
been studied extensively and is thought to be a critical component of P. aeruginosa 
infection and degeneration of lung health in CF patients (68, 73, 74). 
T3SS in P. aeruginosa is used to directly inject exotoxins into its host’s lung 
epithelial cells. T3SS in P. aeruginosa delivers four different exotoxins, which include 
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exotoxin S (exoS), exotoxin U (exoU), exotoxin T (exoT), and exotoxin Y (exoY) (61, 
75).  ExoS and exoT are closely related and are members of the mono-ADP-
ribosyltransferase family, which inactivate eEF-2. In addition, exoS and exoT have an N-
terminal GTPase activating protein that targets the Rho family of GTPases, which are 
molecular switches involved is many common cellular functions. ExoU has 
phospholipase A2 which degrades the plasma membrane of cells to cause cell death (76). 
The activity of ExoY is not completely understood, but it is known to cause inter-
endothelial gaps and vascular leak, which in turn lead to inflammation and exudation (77, 
78). T3SS is well characterized as a potent system necessary for infection in a wide 
variety of flora and fauna (76, 79, 80). 
  1.2.2.2. Siderophores 
 In the case of P. aeruginosa, iron acquisition is essential for infection. Iron is 
normally bound tightly to transferrin or in the case of airways, lactoferrin (81-84). P. 
aeruginosa accomplishes this via two major siderophores: pyochelin and pyoverdin. The 
acquired iron is essential to many of the metabolic processes in P. aeruginosa and is 
involved in the regulation of other virulence factors, such as exoA, proteases, and even 
pyoverdine (81, 85, 86). Interestingly, it has been proposed that iron chelators could be 
used as drugs to treat patients with CF. Iron chelation drugs could have a dual effect of 
preventing P. aeruginosa from acquiring iron and dampening the inflammatory response 
of neutrophils by reducing the production of reactive oxygen species. In the absence of 
iron, reactive oxygen species (ROS) would be dampened due to the major role that iron 
plays in its generation (87).  
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  1.2.2.3. Biofilms and mucoid Pseudomonas 
 P. aeruginosa biofilms that form in the lungs of CF patients pose a deadly threat. 
P. aeruginosa biofilms present problems for immunocompromised patients, as P. 
aeruginosa commonly forms biofilms on hospital equipment such as catheters and 
respirators. These biofilms are bacterial communities directed by the QS system, which 
leads to virulence factor production and increased antibiotic defense (57, 88).  
 In almost all cases of biofilm formation in CF patients, P. aeruginosa eventually 
mutates into a mucoid form that is not found in non-CF patients (89). Mucoid 
Pseudomonas microcolonies are enclosed within a fibrous anionic matrix making them 
further resistant to opsonization, phagocytosis, and antibiotics (41, 90-92). The 
emergence of mucoid Pseudomonas has been correlated with the evolution of antibiotic 
resistance in CF patients (89, 93). 
 Mucoid Pseudomonas bacteria are commonly located in hypoxic masses in the 
airway lumen. These infections are known to penetrate the hypoxic mucus zones and 
respond with the production of alginate, which enhances adhesion (94). Growth in these 
hypoxic environments further increases hypoxia, which in turn produces increased 
anaerobiosis (95). When the research is taken together it illustrates the need for novel 
therapies to prevent and/or destroy mucoid Pseudomonas. The bulk of current research in 
Pseudomonas pathogenicity is focused on this problem (87, 96-100).   
  1.2.2.4. Pyocyanin 
 Pyocanin (N-methyl-1-hydrophenazine) is a toxin produced by P. aeruginosa 
colonies that is responsible for the characteristic blue-green color of P. aeruginosa 
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colonies. Exposure to high concentrations of pyocanin can result in many serious 
complications including: inflammation, disruption of lung airway epithelium, and 
inhibition of lung ciliary motility. In addition, pyocanin also inhibits catalase, which then 
leads to increased oxidative damage. In combination with the over-activity of PMN ROS 
production, the absence of catalase function can be devastating to the lungs of CF 
patients (45, 49, 86, 101). 
 
Figure 1.3. Adaptations of Pseudomonas aeruginosa in the lung of 
individuals with cystic fibrosis. P. aeruginosa is the major cause of death 
in individuals with CF. It is a highly versatile gram-negative bacteria that 
employs a plethora of virulence factors leading ultimately to the formation 
of mucoid Pseudomonas. Mucoid Pseudomonas is largely responsible for 
the chronic and persistent lung infections that are highly resistant to both 
immune and antimicrobial therapy clearance. Adapted from Winstanley C, 
O’Brien S, Brockhurst MA. 2016. Pseudomonas aeruginosa Evolutionary 
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Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections. 
Trends in Microbiology 24:327-337. 
http://creativecommons.org/licenses/by/4.0/ 
1.3. Innate immunity 
 1.3.1. Overview 
 The innate immune system is responsible for distinguishing self from non-self and 
is also the body’s first line of defense which clears infections through a variety of 
methods. Understanding the function of the innate immune system, or rather its 
dysfunction in CF patients, is critical for developing effective therapies. Although CFTR 
is not normally associated with immune health in healthy individuals, it plays a major 
role in the immune response in CF patients. 
 1.3.2. Pattern recognition receptors  
 Pattern recognition receptors (PRRs) are used by the innate immune system to 
identify pathogens by their pathogen-associated molecular patterns (PAMPs). PAMPs are 
made of foreign moieties such as proteins and lipids that are similar within a group of 
pathogens. PRRs reside on the surface of innate immune cells and recognize PAMPS to 
trigger a signaling cascade. Important PRRs for bacterial infections in CF patients include 
Toll-like receptors (TLRs) 2, 4-6, and 9. TLRs have been extensively studied and each is 
known to recognize specific PAMPs that are specific for different classes of bacterial, 
fungal, and viral pathogens. TLRs will recognize specific moieties including: triacyl 
lipopeptides, lipopolysaccharide (LPS), flagellin, and specific CpG motifs. For example, 
TLR-2 is known to be driven by lipoproteins and peptidoglycan from gram-positive 
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bacteria like S. aureus, while TLR-4 is important for the recognition of gram-negative 
bacteria such as P. aeruginosa. In CF patients, TLR4 in the epithelial lung cells is 
reduced, resulting in decreased activation of MyD88 signaling and Trif signaling, both of 
which are involved in pathways linked to type I interferon signaling (INFs) (102). INF 
signaling is known to be necessary in the clearance of multiple lung-associated pathogens 
(103). Interestingly, it has also been shown that CFTR itself is a PRR specific for the O-
side chain of P. aeruginosa LPS and is essential to effectively coordinate an innate 
immune response to P. aeruginosa (104-106). Once a PRR recognizes a PAMP it will 
trigger a signaling cascade, which will result in many downstream actions including: the 
induction of inflammatory signaling, vasodilation, temperature changes, and phagocyte 
recruitment. The recognition and subsequent response to bacterial infections in the CF 
lung is essential to the health of CF patients (23, 107). 
 1.3.3. Cytokines and inflammation  
 At an early age, even before apparent infection, there is evidence of inflammation 
in the airways of people with CF via excessive, defective PMN invasion and overly 
abundant concentrations of cytokines, cytotoxic granules, and free proteases (108). The 
chronic invasion of dysfunctional PMNs yields a constant activation of NF-κB signaling 
resulting in drastically elevated levels of reactive oxygen species (ROS). Therefore, 
concentrations of pro-inflammatory cytokines (IL-8, IL-6, IL-1β, and TNFα) are 
significantly increased in addition to significantly decreased expression of the anti-
inflammatory cytokine IL-10. In healthy lungs, CFTR aids in the moderation of NF- κB 
signaling during oxidative stress by managing the degradation of nuclear factor of κ light 
polypeptide gene enhancer in B cells inhibitor, α (I-κB-α), but in the CF lung this process 
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is dysfunctional due to decreased CFTR function (109). In addition, CFTR mutation leads 
to diminished trafficking of the antioxidants gluthathione (GSH) and thiocyanate (SCN-). 
Without the proper movement of these antioxidants, oxidative stress alters IL-8 
expression and decreases P. aeruginosa clearance (110). 
 1.3.4. Immune cells 
 Innate immune cells are essential in the clearance of pathogens and quickly 
respond to wounding and infection. Innate immune cells include a wide array of cell type 
including mast cells, natural killer cells, and phagocytes. The most immediately 
responding of the innate immune cells are the phagocytes and in particular the 
neutrophils and macrophages. These cells are important in innate immunity because they 
act to phagocytize invading pathogens and destroy them intracellularly through the use of 
specialized compartments with low pH called lysosomes. When a pathogen is 
phagocytized it enters a phagosome, which will be subsequently merged with a lysosome 
to form a phagolysosome. Inside the phagolysosome the pathogens are destroyed via a 
combination of low pH and reactive oxygen species (ROS) (111). Phagocytes like the 
neutrophil can phagocytize and destroy up to 20 bacteria per cell in rapid succession 
(112). 
  1.3.4.1. Respiratory burst 
 An important method employed by phagocytes is the respiratory burst response, 
which releases ROS into the extracellular environment. PMNs and macrophages produce 
the majority of ROS, which includes hydrogen peroxide (H2O2), superoxide anions (O2
-), 
hypochlorous acid (HOCl), and hydroxyl radicals (OH-). ROS are released as a result of 
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phagocytes attempting to destroy engulfed pathogens. The major source of ROS as a 
result of phagocytes is generated by NADPH oxidase (NOX). Once NOX is activated, its 
subunits will be phosphorylated and translocated to the membrane of the phagosome 
where NOX is located. This allows the subunits to associate with the membrane subunits 
of NOX, which will assist in generation of free oxygen radicals by reducing O2 to O2
- 
(113, 114). A dismutation reaction will then follow to produce H2O2. Myeloperoxidase 
(MPO) and inducible nitric oxide synthase (iNOS) are also important in the generation of 
ROS by producing HOCl and nitric oxide (NO-) (115, 116). These two molecules can 
then react with superoxide to form OH-. iNOS expression has been shown to be 
decreased in CF patients and is implicated in their susceptibility of bacterial infections 
(27, 117-120).  
 Previous literature has shown that too much ROS can cause accidental, collateral 
damage, but too little can lead to pervasive and/or chronic infections (117). Moreover, the 
cells that produce ROS can also lead to many diseases like localized lung injury, acute 
respiratory distress syndrome, asthma, and COPD (121). The literature has shown that 
knocking down ncf1, a subunit of NOX, will lead to complete knockdown of NOX and 
subsequent ROS production in phagocytic cells. NOX has been found to be essential in 
the clearance of fungus and continued recruitment of phagocytes. Using time-lapse 
imaging Brothers et al. showed that NOX was essential in promoting the continued 
chemotaxis of macrophages to the site of a Candida albicans fungal infection (122). 
Alternatively, it has been shown that knock down of NOX has led to decreased lung 
tissue damage, reduced inflammation, and decreased viral burden in mice infected with 
influenza (121). Furthermore, some individuals are born with a congenital 
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immunodeficiency called chronic granulomatous disease (CGD), which is characterized 
by a defect in the production of ROS. These individuals suffer from severe recurrent 
bacterial and fungal infections and extensive inflammatory reaction that can result in 
granulomatous lesions (123). Taken together the proper regulation of ROS in an 
individual can be indicative of general health, but the literature has shown conflicting 
results on the benefit versus injury resulting from ROS (1, 124-126). ROS are essential to 
the clearance of many pathogens and their continued study may prove to be important in 
controlling infection in CF patients.  
  1.3.4.2. Polymorphonuclear leukocytes and CF 
 Although PMN accumulation is a known problem for CF patients, how CFTR 
dysfunction in these immune cells plays a role in innate immunity is not well understood 
(127). PMN are the first responders to cites of infection and wounding and play an 
essential role in the clearance of pathogens, but in CF patients PMN have been shown to 
do more harm than good (128, 129). In fact, neutrophil production of elastase is 
positively correlated with decrease lung function in individuals with CF (130, 131). One 
confounding factor in the study of these immune cells in the CF lungs is that a significant 
amount of research has shown immune cells to function normally outside the lung and 
there are no known defects in macrophages or T cells in individuals with CF (6). 
Recently it has been proposed that lung PMNs may be different than PMNs found in the 
blood in CF patients (132-135). Moreover, PMNs in the CF lung have been shown to 
have increased expression of CD39, CXCR4, CD114, and RAGE, which are involved in 
metabolic and stress pathways (136). CF lung PMNs have also been shown to have a 
decreased respiratory burst (134). Controversially, PMNs in newborns with CF had no 
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discernable differences in function when compared with healthy controls (137). These 
results suggest that more research is necessary to fully understand the function of PMNs 
in CF. 
 Macrophages, neutrophils, and eosinophils have a detectable level of CFTR 
expression, which has been proposed in CF patients to interfere with trafficking of 
chloride ions for the production of bacteria killing compound HOCl, generation of the H+ 
gradient across the cellular membrane, activity of NADPH Oxidase, and the control of 
pH in lysosomal compartments used in the destruction of phagocytosed pathogens (127, 
138-142). These results have caused controversy, because an attenuated immune response 
should cause other organs besides the CF lung to be prone to chronic infection, but this is 
not the case. One explanation that has been offered suggests that it may be possible that 
other organs are able to overcome this immune deficit is some way that the lungs cannot 
(112). 
 Furthermore, it has been suggested that PMNs may have a reduced rate of 
apoptosis, explaining their prolonged residence in the CF lung. PMN defense against 
apoptosis may be explained by a resistance to the pro-apoptotic tumor necrosis factor α 
(TNF-α) and the presence of granulocyte-macrophage colony-stimulating factor (GM-
CSF), which is produced in greater concentrations in CF epithelial cells compared to non-
CF epithelial cells (6, 143). In addition, the presence of PMN proteases also prevents 
phagocytosis, which cleaves macrophage receptors and causes decreased recruitment and 
bacterial clearance (144). The exact role of PMN in CF is still not well understood and 
remains highly controversial (129). 
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 1.3.5. Arsenic exposure 
 Arsenic exposure through contaminated drinking water is a health risk to many 
people worldwide. Arsenic is a chemical element and common contaminate in aquifers 
and wells, especially in areas with high levels of granite such as the northeast United 
States (145, 146). Arsenic leaches out of granite and other sediments into groundwater at 
high rates. The Environmental Protection Agency (EPA) has set a limit on arsenic 
concentration in well water to 10 parts per billion (ppb) (i.e. µg/L). Although the limit 
was reduced from 50 ppb to 10 ppb in 2006, it has been proposed that no level is safe. In 
fact, as low as 2 ppb has been shown to dampen the respiratory burst response of 
zebrafish and increase the load of viral and bacterial infections. In addition, arsenic 
exposure at 2 and 10 ppb leads to a significant decrease in antiviral and antibacterial 
cytokines including IL-1β and TNF-α, which can further exacerbate phagocytosis 
reduction already present in CF patients (147, 148). Arsenic has been shown to affect the 
immune response to pathogens, which can potentially lead to increased P. aeruginosa 
infection and is therefore a complication in people suffering from CF (148). In addition to 
the modulation of the immune response to viral and bacterial infection, environmental 
arsenic exposure has also been implicated in impaired CFTR function. Research has 
shown arsenic to increase the c-Cbl-mediated ubiquitination and degradation of CFTR in 
the human lung and to subsequently reduce CFTR chloride secretion, which, when 
defective, is known to cause decreased clearance of pathogens (149, 150). Moreover, in a 
small clinical study 11 patients were identified to have abnormal sweat salt concentration 
with no genetic diagnosis of CF. These 11 patients with high levels of arsenic in their 
drinking water had higher than normal sweat conductivity (151). When taken together 
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these studies point to arsenic contamination in drinking water as a confounding factor in 
CF and bacterial infections. 
 
Figure 1.4. Arsenic concentration sampled from towns in Maine from 2005-
2009. Approximately 10% of Maine wells have arsenic concentrations 
above the Environmental Protection Agency’s maxium limit of 10 
micrograms per liter (µg/L). Image from: Nielsen MG, Lombard PJ, Schalk 
LF. 2010. Assessment of arsenic concentrations in domestic well water, by 
town, in Maine 2005-09. Credit: US Geological Survey. 
  
 
26 
 
 
 
 1.3.6. Non-coding ribonucleic acids 
 Non-coding ribonucleic acids (ncRNAs) are a large group of RNAs that are 
transcribed but not translated. The central dogma of molecular biology includes DNA 
being transcribed into RNA which is then translated into protein, but ncRNA do not 
initiate translation after transcription. Although ncRNA were initially thought to be little 
more than filler that neither increase nor decrease biological fitness, they have been 
studied increasingly over the past few decades. Today, ncRNAs are divided up into two 
main groups based on length: short ncRNAs (sRNAs) (<200 nt) such as microRNAs and 
long non-coding RNAs (lncRNAs) (>200 nt) (152). Both sRNAs and lncRNAs are 
involved in the regulation of the innate immune response (153, 154). 
  1.3.6.1. microRNAs 
 microRNAs (miRNAs) are sRNA molecules that are approximately 22 
nucleotides in length and act to regulate mRNA post-transcriptionally. In short, a primary 
miRNA (pri-miRNA) is transcribed by RNA polymerase II and is characterized by its 
hairpin RNA structure. This hairpin structure is then recognized by Drosha, an RNAse III 
enzyme, and its cofactor DGCR8. These proteins join a complex of proteins to cleave the 
pri-miRNA into precursor (pre-miRNA). The pre-miRNA is then translocated to the 
cytoplasm with the help of Exportin-5 and Ran-GTP where it then interacts with Dicer 
and TRBP. Dicer and TRBP cleave the hairpin and form the miRNA duplex. The strand 
with the least stable 5’ end is chosen to be the guide miRNA while the opposite strand is 
degraded. The guide strand of the miRNA duplex will then be joined to the RNA-induced 
silencing complex (RISC) with the guidance of Ago2. This new complex is called the 
27 
 
 
 
mature miRNA, which will then bind to the 3’ untranslated region of its target transcript 
via the guidance of the RISC. If the miRNA is perfectly complementary to its target it 
will initiate cleavage by Ago2 and if it is imperfectly complementary it will repress the 
translation of the mRNA. In addition, the mature miRNA complex can also cause mRNA 
deadenylation that will shorten the poly(A) tail of its target and lead to degradation (154-
156). The expression of over 70 percent of all protein coding genes is regulated by 
miRNAs, which means that miRNAs play a role in regulation across most critical 
biological processes. Interestingly, one single miRNA may regulate many distinct 
transcripts or multiple miRNAs may regulate a single transcript.  
 Furthermore, miRNAs are known to play a role in a multitude of complicated 
human diseases including Down syndrome, Huntington’s disease, cancer, and CF. 
miRNA-223 controls the production and activation of granulocytes and miRNA-223 
ablation in mice has resulted in hypermature, hypersensitive granulocytes (157). miRNAs 
have been implicated in the regulation of important factors of CF including inflammatory 
signaling and the unfolded protein response (UPR) (158). One miRNA of interest, miR-
199a-5p, is involved in the UPR in chronic obstructive pulmonary disease and may prove 
to be an interesting target for CF research (159). 
  1.3.6.2. Long non-coding RNAs 
 Long non-coding RNAs (lncRNAs) are non-protein coding RNA that are greater 
than 200 nucleotides long, and are broken up into three categories: intergenic, intronic 
overlap, and antisense exonic overlap (Figure 1.5). These lncRNAs are involved in 
numerous biological processes including regulation of the cell-cycle, apoptosis, cell 
28 
 
 
 
identity, and the innate immune response (153, 160, 161). It is believed that there are 
more than ten transcriptional units that overlap each protein-coding gene with the vast 
majority of them being lncRNAs (162). There is controversy over the functionality of 
most lncRNA, because in most cases transcription produces short and mostly unstable 
transcripts that have a significantly lower level of expression compared to protein-coding 
genes (163, 164). This may be the case for most lncRNA, but it is believed that if even 
10% were functional there would be greater than a thousand known lncRNAs that would 
have a role in biology (153). In fact, there have been many recent cases where functional 
lncRNAs are found and expressed at higher than expected concentrations (153, 164-166).  
 The exact mechanisms of function of lncRNAs are still being discovered, but 
many have been elucidated to be necessary for proper gene control across all kingdoms. 
In the beginning of lncRNA research it was discovered that a non-coding protein, Xist, 
plays an important role in the epigenetic regulation of X-chromosome inactivation (XCI). 
XCI is a vital process in mammals that ensures that females have only one copy of the X 
chromosome in each cell. Xist was found to be expressed only on the inactive X 
chromosome and essential for the silencing process (162, 167, 168). The discovery of 
Xist and its function changed the way that researchers viewed lncRNA and has led to the 
discovery of many novel functions and roles for lncRNA across biology. lncRNAs have 
also been shown to act as molecular scaffolds for organization in ribonucleoprotein 
complexes and chromatin states (166). Moreover, they have been found to be involved in 
cotranscriptional regulation, binding proteins and chromatin, nucleation of nuclear 
domains, pairing with other RNA, acting as molecular decoys, and more functions are 
believed to exist that have yet to be discovered (Figure 3.1.) (153). lncRNAs are the true 
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frontier in molecular biology and their continued discovery and characterization may be 
important for discovery of novel therapies for human diseases. 
 In an effort to identify noncoding RNAs and their corresponding genes more 
simply, most large scale analyses have focused on long intergenic (or intervening) 
noncoding RNAs (lincRNAs). lincRNAs have the benefit of neither having overlapping 
exons nor protein coding regions, nor are they antisense to a protein coding gene. 
lncRNAs as a whole are considered to be largely nonfunctional transcripts, but 
burgeoning research is finding novel functions for previously nonfunctional lncRNAs. 
Many large scale experiments have been conducted to catalog lncRNA loci and 
transcripts across many species in an effort to better understand their roles in biology 
(153). Zebrafish lncRNA loci and transcripts have also been cataloged, which may prove 
to be useful in elucidating the function of lncRNA in a relatively tractable animal model 
(161, 169, 170). Interestingly, like miRNAs, lncRNAs have also been implicated in CF, 
with many lncRNAs differentially expressed between CF and non-CF individuals and 
many of the lncRNAs related to inflammation in the CF bronchial epithelium cells (152). 
It is therefore important to continue research into the relationship between lncRNAs and 
inflammation in individuals with CF.  
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Figure 1.5. Categories of long non-coding RNA. Adapted from Pauli A, 
Valen E, Lin MF, Garber M, Vastenhouw NL, Levin JZ, Fan L, Sandelin 
A, Rinn JL, Regev A. 2012. Systematic identification of long noncoding 
RNAs expressed during zebrafish embryogenesis. Genome research 
22:577-591. 
1.4. Zebrafish as a model organism 
 The zebrafish (Danio rerio) is a model that has become increasing popular in the 
past few decades, due initially to an effort to reduce, replace, and refine animal models 
used in research. Though what initiated the use of the zebrafish as an animal model is still 
important today, the uniqueness of the model is what has brought them into prominence. 
The zebrafish model has found its own niche in animal research due to a many beneficial 
characteristics, including high fecundity and production of young ex utero, which allows 
simplified injection with a large sample size. Moreover this allows for high throughput 
sequencing and analyses. Furthermore, the zebrafish’s rapid development allows for the 
creation of all of their primordial organs within the first 24 hours post fertilization. In 
addition, their cost is low and maintenance is relatively simple, compared to many other 
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popular models such as the mouse. In a single facility thousands of fish can be 
maintained by a single technician. The optical transparency of zebrafish allows for 
visualization and imaging of infection with fluorescent pathogens and/or immune cells in 
vivo and in real time, which is not possible in other nontransparent animal models (171-
173). Zebrafish are also genomically and physiologically similar to mammals (174, 175). 
Importantly, there are many genetic tools available for the zebrafish, which allows 
researchers to study the immune system and host-pathogen interactions in a way that 
cannot be replicated in mammalian models or cell culture (171).  
 In addition to the many benefits of using zebrafish in research, they also have an 
immune system that is highly homologous to that of humans and haven been 
characterized in the context of many human diseases and infections including CF (176-
178). At 48 hours post fertilization the zebrafish has a functional innate immune system 
and until about 4 to 6 weeks post fertilization they are without an adaptive immune 
system (172). This distinction of time between the maturation of the two immune systems 
allows researchers to study the innate immune system either alone or in combination with 
the adaptive response. The components of the immune system are also highly conserved 
between zebrafish and human, with zebrafish expressing an almost complete set of toll-
like receptors in addition to cytosolic sensors and signaling molecules, which allows 
researchers to target specific pathways and systems. Although the intermediates of some 
of these pathways may be different, the functionality is conserved (173). 
 Zebrafish are also susceptible to bacterial, viral, and protozoan infections 
including P. aeruginosa, which are managed by the immune system in much the same 
way as the human immune system. Zebrafish are susceptible to P. aeruginosa and 
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respond to the infection by upregulating many characteristic cytokines such as IL-1, 
TNF-α, and CXCL8L1/L2 (IL-8). Leukocytes like neutrophils and macrophages also 
respond to infection immediately following viral, bacterial, and fungal infections (122, 
177). 
 Recently the zebrafish was established as a model for CF and P. aeruginosa 
infection. It was found that CFTR morphant zebrafish have a reduced respiratory burst, 
decreased neutrophil migration, and decreased clearance of P. aeruginosa. In addition, it 
was shown that zebrafish challenged with other common respiratory infections in CF 
patients, did not show the same resistance to bacterial clearance that was see in P. 
aeruginosa infected zebrafish. The LasR QS system of P. aeruginosa was found to be 
responsible for the zebrafish’s reduced ability to clear the infection (177). When taken 
together, the zebrafish is a good research animal to model the innate immune response to 
P. aeruginosa in a CFTR morphant system.  
 The zebrafish genome is greater than 70% homologous to human and is 
completely sequenced, which allows for the use of targeted genetic manipulation with the 
use of tools like clustered regularly interspaced short palindromic repeats (CRISPR), 
zinc-finger nucleases (ZFNs), and transcription activator-like nucleases (TALENs), and 
morpholino oligonucleotides (MOs). CRISPR is an important tool for manipulation 
available to zebrafish researchers. The CRISPR system is a powerful tool that is natively 
found in bacteria and archaea as a defense mechanism. This system adapts by 
incorporating sequences derived from foreign pathogens into a small-RNA-based 
repertoire. This repertoire is then able to prime a complex of proteins to recognize and 
destroy invading pathogens (179). In zebrafish research this can be used as a means to 
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knock-out target genes by customizing single guide RNAs (sgRNAs) that can direct Cas9 
to endogenous zebrafish genes. Cas9 is an endonuclease that can cause site-specific DNA 
cleavage, which can therefore knock-out targeted zebrafish genes (180). 
 ZFNs can also act similarly to CRISPR by targeting specific loci in zebrafish and 
disrupt targeted genes. ZFNs act to target a specific locus and cause a double-break in the 
DNA that is subsequently repaired. During the repair process small insertions and 
deletions are generated. When ZFNs were designed and injected into zebrafish embryos 
to target the no tail/Brachyury (ntl) gene, characteristic mutations were observed. Unlike 
CRISPR, which completely knocks-out targeted genes, ZFNs were only able to disrupt 
ntl and cause a loss of function is about half of the injected embryos with an average 
function of 20% (181). This approach, therefore, is used less often with the advent of the 
CRISPR/Cas9 system. In addition, the engineering of ZFNs has proven to be challenging 
due to the necessity to account for the effects of each individual “finger” in the zinc-
finger nucleases (182).  
 Another useful system for genome editing in zebrafish are TALENs. TALENs are 
transcription activator-like effector repeats fused to the nonspecific Fokl cleavage domain 
that are constructed to influence specific double-stranded breaks in cells. TALENs are 
very efficient and are capable of altering the genes at or near the site of the double-
stranded break. TALENs are also relatively easy to engineer and can be formulated to 
target most sequences (182, 183).  
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 Morpholinos are antisense oligonucleotides that are able to bind to 
complementary RNA and either prevent transcription or modify RNA splicing and are 
therefore able to knock-down specific genes such as the cftr gene. Morpholinos can be 
injected into the embryos at the one-cell stage, which will effectively knock-down the 
targeted gene in every cell for a limited duration, usually remaining effective for 3-4 days 
post injection (184). 
  One important genetic change that has been made to zebrafish is the establishment 
of a transgenic zebrafish line, tg(MPX:GFP). This line expresses GFP under the control 
of the promotor for the neutrophil-specific-myeloperoxidase (MPX), which yields green 
fluorescent neutrophils. This line of transgenic zebrafish has been instrumental in 
investigating the inflammatory response of neutrophils to wounding and infection, as well 
as characterizing their migration (185, 186). A crucial aspect of neutrophils, among other 
granulocytes, in the innate immune response is the production of a respiratory burst 
which results in the release of ROS. ROS have an important role in clearing invading 
pathogens after an infection. Another benefit to the zebrafish as a research model is the 
relative ease of measuring ROS via the recent development of cheap, efficient assays. In 
short, zebrafish are exposed to reduced 2’7’-dichlorodihydrofluorescein diacetate and 
phorbol 12-myristate 13 –acetate (PMA). PMA is used to activate protein kinase C and 
subsequently induce a respiratory burst from immune cells. During the assay the 2’7’-
dichlorodihydrofluorescein diacetate is oxidized and becomes fluorescent, and can 
therefore be measured with a standard plate reader (187, 188). 
 
35 
 
 
 
 The many beneficial characteristics of the zebrafish combined with its 
susceptibility to P. aeruginosa and the ability to knock-down the CFTR gene, make it an 
excellent animal model for the study of the role of ncRNA in innate immunity and 
environmental interactions. In addition, the availability of cataloged lincRNA loci and 
transcripts allows researchers to investigate the roles of specific lincRNAs to potentially 
elucidate the roles in immunity. It is evident that the zebrafish is a powerful animal model 
for research into immunity. 
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CHAPTER 2 
KNOCKDOWN OF MIRNA-199 IMPROVES RESPONSE  
TO INFECTION BY P. AERUGINOSA 
2.1. Introduction 
 Cystic fibrosis (CF) is a multi-organ orphan disorder that is caused by mutations 
in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). CFTR is a gene 
that codes for a chloride ion channel that is expressed in epithelial cells, lymphocytes, 
polymorphonuclear (PMN) cells, and many more cell types, and is responsible for the 
regulation of ion transport. When CFTR is mutated it causes a loss of airway surface 
liquid from improper transport of ions, which results in thick mucus formation. The 
formation of thick mucus, along with poor pancreas function leads to the bulk of the 
clinical manifestations of CF, including digestive issues, malnutrition, and improper 
clearance of lung infections (6). Although CF is a multi-organ disease, the majority of CF 
patients will succumb to lung infections, with P. aeruginosa being the most common 
pathogen in adult CF patients (23, 49). Antibiotics and other therapies are initially 
effective for improving lung function, but successive infections and myriad P. 
aeruginosa virulence factors and biofilm/mucoid formation leads to an infection that 
cannot yet be overcome by modern medicine.  
 Much effort has been put into developing novel therapies to treat and even cure 
people with CF, but at this time nothing can prevent the almost always fatal lung 
infections. To better understand CF and the role that P. aeruginosa is playing in 
immunity, the zebrafish model has been employed. Zebrafish (Danio rerio) is a member 
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of the teleost family of vertebrates and has become an excellent animal model for the 
study of many human diseases and infections. The zebrafish is genomically and 
physiologically similar to humans and utilizes its innate immune system solely for the 
first 4-6 weeks of life (172, 174, 175). The distinction between innate and adaptive 
immunity, combined with the availability of genetic tools, efficient assays, translucent 
body, high fecundity, and relatively low cost of care and maintenance allows researchers 
to study the immune system and host pathogen interactions in a way that could not be 
replicated as effectively in other animal models or cell culture (171).  
 Recently, the zebrafish has been shown to be a good animal model for CF 
knockdown (KD) and P. aeruginosa infection (177). Phennicie et al. found that CFTR 
KD via morpholino oligonucleotides (MO) in wildtype (wt) zebrafish leads to a 
dampened respiratory burst and when infected with P. aeruginosa the zebrafish displayed 
a statistically higher bacterial burden in the CFTR KD embryos when compared to 
control embryos. In addition, the migration of neutrophils was found to be decreased in 
the CFTR KD zebrafish compared to the control zebrafish, which could potentially 
explain the decreased respiratory burst and consequently higher bacterial burden (189). 
 In addition to the major problem of P. aeruginosa infection in CF patients, arsenic 
is another factor that has potential to be dangerous to CF patients living in areas with high 
concentrations of this element in well water. Arsenic has recently been shown to degrade 
CFTR and to subsequently reduce chloride secretion, thus exacerbating CF (149). In 
addition, arsenic concentration has been correlated with increased sweat chloride 
conductivity in a small clinical trial of non-CF patients in Bangladesh (151). 
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 Non-coding RNA (ncRNA) such as microRNA (miRNA) has been implicated in 
many human diseases like CF, but little is known about their potential in therapeutics and 
CF research (158, 160). miRNA are short RNA molecules of about 22 nucleotides that 
regulate mRNA post-transcriptionally. One miRNA, miRNA-199a-5p, is even involved 
in the unfolded protein response (UPR) in chronic obstructive pulmonary disease and 
could prove to be an interesting target for CF research (159). In short, ncRNA like 
miRNA could be important to future CF research and the production of novel treatments. 
 To examine the effects that P. aeruginosa and arsenic have on CF and their 
relation to immunity and the regulation of ncRNA, a large RNA-Sequencing (RNA-Seq) 
experiment was designed (Figure 2.1). Zebrafish were injected with either 2.5 ng of a co-
injection mixture of two CFTR MO or 2.5 ng of control MO at the 1-cell stage, as 
explained by Phennicie et al. (177). Starting after the initial collection of zebrafish 
embryos, arsenic was added to the egg water at 0, 2, or 10 parts per billion (ppb) and 
changed daily until RNA isolation. At 48 hours post fertilization (hpf) the zebrafish were 
injected with 50 CFU/embryo of P. aeruginosa into the Duct of Cuvier (DC). At 6 hours 
post infection (hpi) the zebrafish were homogenized and RNA was isolated for RNA-Seq. 
Both polyA+ selected mRNA and small RNA sequencing libraries were prepared for 
each sample and then sequenced allowing for characterization of mature mRNAs and 
small RNAs, such as miRNAs 
 Through analysis of the small RNA-Seq data, miRNA-199-1-3p (miRNA-199) 
was shown to be differentially expressed during infection and arsenic exposure (Figure 
2.2.). miRNA-199 is highly conserved in both humans and zebrafish and has been 
associated with many potentially target protein-coding genes (190, 191). Several 
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experiments were conducted by Gagne and Sullivan et al. (unpublished) to understand the 
role miRNA-199 in innate immunity. The found miRNA-199 expression to increase by 
2.4 fold upon CFTR KD and 10 ppb arsenic exposure at 6 hpi as measured by the RNA-
Seq analysis (Figure 2.3a.). When targeted by a MO, miRNA-199 morphants displayed a 
significant reduction in bacterial burden at 6 hpi (Figure 2.3b). Furthermore, miRNA-199 
KD markedly increased survival of zebrafish when infected with P. aeruginosa over a 5-
day period, compared to control embryos infected with P. aeruginosa (Figure 2.3c) 
(Gagne and Sullivan et al., unpublished).  
 
 
 
 
 
40 
 
 
 
 
Figure 2.1. Experimental Design of RNA-Seq. Zebrafish embryos at the 1-
cell stage were injected with 3 nl of a solution containing 0.05% phenol red, 
1x Danieau buffer, nuclease-free water, and either 2.5 ng of a co-injection 
mixture of two CFTR MO or 2.5 ng of control MO as described by 
Phennicie et al. (177). Starting after the initial collection of zebrafish 
embryos and changed daily, arsenic was added to the egg water at 0, 2, or 
10 parts per billion (ppb). At 48 hours post fertilization (hpf) the zebrafish 
were injected with 50 CFU/embryo of P. aeruginosa into the Duct of Cuvier 
(DC). At 6 hours post infection (hpi) the zebrafish were homogenized and 
RNA was isolated for cDNA library preparation and eventual RNA-
sequencing.  
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Figure 2.2. MA plot of miRNA-199 dysregulation. The MA plot compares 
the regulation of miRNA-199 during P. aeruginosa infection and 10 ppb 
arsenic exposure compared to control fish injected with PBS and not 
exposed to arsenic. miRNA-199 (miR-199) is more highly expressed and 
displayed an increased fold change compared to most other miRNAs 
assayed leading Gagne and Sullivan et al to investigate its function further. 
The y-axis represents log2 fold change and the x-axis represents the mean 
expression level (log2(Counts per million) units). Adapted from Gagne and 
Sullivan et al., unpublished data.  
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Figure 2.3. Knockdown of miRNA-199 improves response to infection by 
P. aeruginosa. (a) RNA-Seq reveals that miRNA-199 is differentially 
expressed in response to arsenic exposure in cftr morphants. (b) The 
respiratory burst response is significantly dampened in response miRNA-
199 KD zebrafish embryos. (c) miRNA-199 KD leads to an increase 
survival in zebrafish embryos infection P. aeruginosa compared to 
zebrafish embryos injected with PBS. All experiments are representative of 
3 biological replicates. Statistical analyses were calculated with the 
unpaired t test. Error bars represent standard error of the mean. Adapted 
from Gagne and Sullivan et al., unpublished data. 
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 To further understand the protective role of miRNA-199 in innate immunity a 
bacterial burden and respiratory burst assay were conducted in the context of CFTR KD, 
arsenic exposure, and bacterial infection. The data from the bacterial burden was 
inconclusive due to a high degree of variability within each experiment. The respiratory 
burst, however, confirmed that miRNA-199 is having a protective role on ROS 
production in control zebrafish, which is consistent with Gagne and Sullivan et al. These 
results show that miRNA-199 is important in the modulation of the respiratory burst 
response during bacterial infection. In addition, these data further provide support for the 
research of ncRNA and their role in innate immunity and infection.  
2.2. Materials and methods 
 2.2.1. Zebrafish care and maintenance 
 The zebrafish were maintained in agreement with the guidelines established by 
the University of Maine Institutional Animal Care and Use Committee (IACUC). 
Zebrafish embryos were collected at the one-cell stage of development from natural 
spawns of adult AB zebrafish. They were kept at 28 ̊C on a 16 hour light and 8 hour dark 
cycle. The zebrafish were grown in egg water (60 mg/L Instant Ocean sea salts), which 
was changed daily. Deceased zebrafish were collected with a plastic pipette and disposed 
of daily. Unused zebrafish, along with all fish at the end of each experiment, were 
euthanized by immersion in a lethal dose of tricaine followed by proper disposal.  
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 2.2.2. Morpholino preparation and injection 
 Morpholinos (MO) were prepared as instructed by Gene Tools (Philomath, OR). 
CFTR morpholinos were generated against the zebrafish cftr gene (GenBank accession 
no. NM_001044883) as described by Phennicie et al. (177). Zebrafish cftr KD was 
achieved by injection a combination of CFTR I1E2 MO (5’- 
CCACCTGTAAATATTCAGAGCAGAT-3’) and CFTR Trans MO (5’-
CATCCTCCACAGGTGATCTCTGCAT-3’). CFTR I1E2 MO anneals to the boundary 
between intron 1 and exon 2 of the cftr transcript and yields a deletion of exon 2. CFTR 
Trans MO blocks translation of the cftr transcript by binding to its AUG start site. 
Embryos were co-injected with 1.25 ng of each CFTR MO.  
 miRNA-199 MO (Gene Tools, Philomath, OR) was designed using sequence 
information from the Sanger Institute’s miRBase (Accession no. MIMAT0003155). miR-
199-1-3p MO was designed to target the dicer cleavage site on the originally annotated 
mature (star) strand to prevent mature miRNA formation (5’-
TCTAACCAATGTGCAGACTACTGTA-3’). Embryos were injected with 12 ng of 
MiR-199-1-3p MO into the yolk sac at the 1-2 cell stage. 
 Control MO (Gene Tools, Philomath, OR) was also injected into the 1-2 cell stage 
of zebrafish embryos (5’-CCTCTTACCTCAGTTACAATTTATA-3’). Control MO 
targets a human beta-globin intron mutation that causes beta-thalassemia. This MO, 
however, does not cause a change in phenotype and is used broadly as a negative control.  
Embryos were injected with 2.5 ng, 12 ng, or 14.5 ng control MO into the yolk sac. All 
MO injections were performed using a MPPI-2 microinjection apparatus (Applied 
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Scientific Instruments, Eugene, OR) using pulled microcapillary needles (Sutter 
Instruments, Novato, CA). After injection the zebrafish embryos were placed in 50 mL of 
egg water and maintained at 28 ̊C. 
 2.2.3. Bacterial preparation 
 P. aeruginosa strain PA14 (p67T1) was used for all infections (Singer et al., 
2010). PA14 (p67T1) contains a constitutive plasmid-encoded RFP variant of d-Tomato, 
which was engineered by Shaner et al. (192). Bacterial colonies were grown on 15 g/L 
bacteriological agar (Affymetrix, Cleveland, OH) combined with 25 g/L LB (Affymetrix, 
Cleveland, OH) supplemented with 750 µg of ampicillin/mL (Sigma-Aldrich, St. Louis, 
MO). Two days prior to infection, bacteria were streaked out on the aforementioned 
plates and grown for 24 hours at 37 ̊C. The night before infection a single colony was 
picked using a p200 micropipettor tip and placed in a glass test tube containing 4 mL of 
25 g/L LB broth (Affymetrix, Cleveland, OH) supplemented with 750 µg of 
ampicillin/mL (Sigma-Aldrich, St. Louis, MO). The test tube was placed in a shaking 
incubator (250 rpm) for 12-16 hours at 37 ̊C. The following morning a sample of the 
bacterial culture was diluted 1:20 in a 1 mL cuvette with PBS (Life Technologies, Grand 
Island, NY) and measured using a spectrophotometer at 600 nm. An OD of 1 was added 
to 25 mL of 25 g/L LB (Affymetrix, Cleveland, OH) supplemented with 750 µg of 
ampicillin/mL (Sigma-Aldrich, St. Louis, MO) in a 125 mL Erlenmeyer flask and placed 
on a shaking incubator (250 rpm) for 2-4 hours. The culture was then added to a 50 mL 
plastic conical tube and centrifuged at 5000 x g for 5 min at 4 C̊. The supernatant was 
decanted and the pellet was re-suspended and washed in 3 ml of PBS (Life Technologies, 
Grand Island, NY). This step was repeated 3 times and the pellet re-suspended in 2 mL of 
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PBS (Life Technologies, Grand Island, NY). The culture was then decanted into a 5 mL 
syringe (BD, Franklin Lakes, NJ) connected to a 30 gauge x 1/2 needle (0.3 mm x 13 
mm) (BD, Franklin Lakes, NJ) and expelled into a sterile 15 mL conical tube. This step 
was repeated twice and 50 µL of the bacterial culture was diluted 20x into 950 µL of PBS 
(Life Technologies, Grand Island, NY) in a clear plastic cuvette. The cuvette was read at 
600 nm in a spectrophotometer. Bacterial cultures were diluted in PBS (Life 
Technologies, Grand Island, NY) and 50 µL of 5% phenol red (PR) (Sigma-Aldrich, St. 
Louis, MO) to achieve a 50 CFU/embryo injection. PR was used to visualize the injection 
into the embryo. 
 2.2.4. Bacterial injection 
 The zebrafish were dechorionated manually using Style 5 Dumont tweezers 
(Electron Microscopy Sciences, Hatfield, PA) at 2 days post fertilization (2dpf). Embryos 
were then anesthetized in 4 mg/mL Tricaine solution (Western Chemical, Ferndale, WA) 
and lined up on a 3% agar gel petri dish. P. aeruginosa was then injected into the 
embryo’s Duct of Cuvier with 3 nL of P. aeruginosa strain PA14 (p67T1) to a final 
concentration of 50 CFU/embryo. The LD50 of PA14 (p67T1) was determined previously 
to be 50 CFU/embryo. This concentration resulted in 50% mortality by 48 hpi (Phennicie 
et al., 2010). Injection was done using a MPPI-2 microinjection apparatus (Applied 
Scientific Instruments, Eugene, OR) using pulled microcapillary needles (Sutter 
Instruments, Novato, CA). All embryos were screened with a Zeiss fluorescence 
screening microscope (Carl Zeiss AG, Oberkochen, Germany) for Texas Red 
fluorescence. Any embryos that were improperly injected and did not fluoresce red were 
removed and euthanized according to IACUC protocol with a lethal dose of Tricaine 
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(Western Chemical, Ferndale, WA).  After injection, the zebrafish embryos were 
maintained at 28 ̊C. 
 2.2.5. Arsenic exposure 
 A 10mM sodium arsenite (NaAsO2) (Fisher Scientific, Hampton, NH) stock was 
made in 50 mL nanopure water and filtered with a 0.2 µM syringe filter. The filtered 
solution was stored at -20 ̊C in 1 mL aliquots in 1.5 mL microcentrifuge tubes. After MO 
injections zebrafish embryos were placed in 50 mL of egg water containing either 0 or 10 
ppb arsenic. The egg water containing arsenic was changed daily. 
 2.2.6. Bacterial burden 
 At 8 hours post injection 20 zebrafish embryos from each treatment group (Table 
2.1.) were washed in PBS (Life Technologies, Grand Island, NY). They were then 
individually added with 200 µL of PBS via a shortened p1000 tip on a p1000 
micropipettor to separate 1.5 mL microcentrifuge tubes containing two 3.5 mm stainless 
steel balls (Next Advance, Averille Park, NY). The tubes were added to a Bullet Blender 
(Next Advance, Averille Park, NY) for 2 min at maximum speed and then centrifuged for 
30 seconds at 13.5 x g in a desktop centrifuge. 100 µL from each tube was added to a 
separate agar plate containing 15 g/L bacteriological agar (Affymetrix, Cleveland, OH) 
combined with 25 g/L LB (Affymetrix, Cleveland, OH) supplemented with 750 µg of 
ampicillin/mL (Sigma-Aldrich, St. Louis, MO). Each sample was plated with a plastic, 
disposable culture stick and then placed in a 37 ̊C culture incubator for 24 hours. The 
CFU were counted and recorded after 24 hours. Error bars represent the standard error of 
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the mean (SEM). The data represent three independent trials were analyzed via ANOVA 
4-factor analysis using JMP 8.01 (SAS, Cary, NC). 
Table 2.1. Treatment groups for bacterial burden 
Group No. Arsenic 
Concentration 
(parts per 
billion) 
2.5 ng cftr MO or 
2.5 ng control MO 
(cftr or control) 
12 ng miRNA-
199 MO or 12 
ng control MO 
(control or 
miRNA-199)  
P. 
aeruginosa 
Infection  
(+ or -) 
1 0 ppb control control - 
2 0 ppb control control + 
3 0 ppb cftr control - 
4 0 ppb cftr control + 
5 10 ppb control control - 
6 10 ppb control control + 
7 10 ppb cftr control - 
8 10 ppb cftr control + 
9 0 ppb control miRNA-199 - 
10 0 ppb control miRNA-199 + 
11 0 ppb cftr miRNA-199 - 
12 0 ppb cftr miRNA-199 + 
13 10 ppb control miRNA-199 - 
14 10 ppb control miRNA-199 + 
15 10 ppb cftr miRNA-199 - 
16 10 ppb cftr miRNA-199 + 
 
2.2.7. Respiratory burst assay 
 The respiratory burst assay was performed as described by Hermann et al. and 
Goody et al. (187, 188). The treatment groups are categorized in Table 2.2. Twelve 
embryos per treatment group were exposed to phorbol 12-myristate 13-acetate (PMA) 
and 12 were not. The plate was read using a Synergy2 plate reader (Biotek, Winooski, 
VT). The plate was shaken for 5 seconds and then measurements were taken with an 
excitation of 485 nm and emission of 528 nm. Error bars represent SEM. The data 
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represent three independent trials and were analyzed via ANOVA 4-factor analysis using 
JMP 8.01 (SAS, Cary, NC). 
Table 2.2. Treatment groups for respiratory burst assay 
Group No. Arsenic 
Concentration 
(parts per 
billion) 
2.5 ng cftr MO or 
2.5 ng control MO 
(cftr or control) 
12 ng miRNA-
199 MO or 12 
ng control MO 
(control or 
miRNA-199)  
PMA 
(+ or -) 
1 0 ppb control control - 
2 0 ppb control control + 
3 0 ppb cftr control - 
4 0 ppb cftr control + 
5 10 ppb control control - 
6 10 ppb control control + 
7 10 ppb cftr control - 
8 10 ppb cftr control + 
9 0 ppb control miRNA-199 - 
10 0 ppb control miRNA-199 + 
11 0 ppb cftr miRNA-199 - 
12 0 ppb cftr miRNA-199 + 
13 10 ppb control miRNA-199 - 
14 10 ppb control miRNA-199 + 
15 10 ppb cftr miRNA-199 - 
16 10 ppb cftr miRNA-199 + 
 
2.3. Results 
 2.3.1. miRNA-199 shows inconclusive effect on overall P. aeruginosa bacterial 
 burden  
 The preliminary experiments from Gagne and Sullivan et al. have revealed a role 
for miRNA-199 in the respiratory burst response to bacterial infection in zebrafish. A 
bacterial burden was therefore conducted to determine if miRNA-199 was effecting the 
overall bacterial concentration in the zebrafish. Zebrafish were grown up to 48 hpf and 
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injected with 50 CFU/embryo P. aeruginosa or PBS. At 8 hpi the zebrafish were 
homogenized and plated separately. The plates were counted 24 hours later, but did not 
reveal conclusive results (Figure 2.4.). The three biological replicates that were 
performed were inconsistent. Replicate 1 (Figure A.1.) and replicate 2 (Figure A.2.) 
showed opposite effects for zebrafish co-injected with control and miRNA-199 MOs 
compared to control zebrafish. Replicate 2 showed miRNA-199 KD causing a decrease in 
bacterial burden where replicate 1 showed an increase bacterial burden. Replicate 2 
showed an increase in bacterial burden when zebrafish were exposed to 10 ppb arsenic 
compared to 0 ppb arsenic. In addition, CFTR KD appeared to reduce bacterial burden 
when compared to control. miRNA-199 KD in CFTR KD zebrafish showed an increased 
burden when compared to CFTR KD control fish. Furthermore, replicate 3 (Figure A.3.) 
showed no significant change in the data.  
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Figure 2.4. miRNA-199 shows inconsistent effects on P. aeruginosa 
bacterial burden. Three biological replicates were combined and analyzed 
using a four-factor ANOVA statistical analysis. The results show no 
significant change between the experimental groups and when the separate 
replicates were analyzed for statistical significance there appeared to be no 
discernable trend within the experimental groups between the trials. The 
biological replicates are shown individually in Appendix A. 
 2.3.2. miRNA-199 plays a role in the regulation of respiratory burst 
 A respiratory burst assay (RBA) was performed to elucidate the role of miRNA-
199 in zebrafish that were co-injected with CFTR and exposed to arsenic. Our controls 
show that when CFTR MO is co-injected with control MO a reduced respiratory burst is 
observed. In addition, arsenic decreased the respiratory burst. When zebrafish are co-
injected with control and miRNA-199 MOs and compared to control zebrafish they 
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display a dampened production of reactive oxygen species (ROS). In addition, in the 
context of arsenic, CFTR KD causes a decrease in ROS production when compared to 
control. Furthermore, in zebrafish that were co-injected with CFTR and miRNA MOs an 
increased respiratory burst was observed when compared to both zebrafish that were co-
injected with CFTR and control MOs and zebrafish that were injected with control and 
miRNA-199 MOs.  
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Figure 2.5. miRNA-199 plays a role in the regulation of respiratory burst. 
Three biological replicates of respiratory burst assays were combined and 
analyzed with a 3-factor ANOVA statistical analysis. Regardless of arsenic 
exposure CFTR KD leads to a dampened respiratory burst. Arsenic 
exposure also dampens ROS production in zebrafish co-injected with 
control and miRNA-199 MOs. Zebrafish that were exposed to arsenic and 
co-injected with control and miRNA-199 MOs also showed dampened ROS 
production when compared to control zebrafish exposed to arsenic. 
Conversely, when zebrafish co-injected with CFTR and miRNA-199 MOs 
were compared to the zebrafish co-injected with control and miRNA-199 
MOs an increased respiratory burst was observed in the zebrafish co-
injected with CFTR and miRNA-199 MOs. 
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2.4. Discussion 
 Unpublished data by Gagne and Sullivan et al. showed a protective role for 
miRNA-199 in immunity and infection. The results showed that miRNA-199 KD resulted 
in a dampened respiratory burst response in wild-type zebrafish along with increased 
survival in miRNA-199 KD fish compared to control KD fish infected with P. 
aeruginosa. At first glance these two results appear to be conflicting, but it is possible 
that reducing the respiratory burst is increasing survival by limiting collateral damage 
from PMN respiratory burst. An immune response that is too intense leads to damage, 
while an immune response that is too weak will result in decreased pathogen clearance 
and yield higher bacteria burden. In CF patients PMNs and their markers are positively 
correlated with decreased lung function (44). CF patients are unable to clear pathogens 
due to the ineffectiveness of PMNs and the virulence factors of P. aeruginosa. These 
individuals are at risk for unresolved infections as a result of chronic inflammation (112, 
193). These results together suggest that miRNA-199 is an important mediator of 
immunity and possibly imply a role in regulation of ROS which can lead to a more 
controlled immune response during infection. In addition, miRNA-199 KD could 
potentially rescue respiratory burst and bacterial burden in CFTR KD zebrafish. 
 To determine if the protective role of miRNA-199 translated to decreased 
bacterial burden, which is suggested by its role in increased survival, a bacterial burden 
assay was conducted. Three biological replicates were performed, with zebrafish that 
were injected with either CFTR or control MOs and either miRNA-199 or control MOs, 
exposed to 10 or 0 ppb arsenic, and infected with P. aeruginosa or control (PBS). When 
the three replicates were compiled and a 4-factor ANOVA statistical analysis was 
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performed, no significant change between the experimental groups was observed. The 
three biological replicates were inconsistent with each other and therefore no conclusions 
could be drawn about the role of miRNA-199 in infection. We expected arsenic and 
CFTR KD to increase the bacterial burden as described by Nayak et al, and Phennicie et 
al, respectively (147, 177). In addition, for the same reasons outlined above, we expected 
miRNA-199 KD to decrease bacterial burden and correlate with the increased survival 
observed by Gagne and Sullivan et al., but our results were too inconsistent to permit us 
to reach any conclusion.  
 Although the replicates are not consistent with each other, replicate 2 (A.2.) does 
reveal a trend that is consistent with previously published data (147, 177). Arsenic was 
shown to increase the bacterial burden in zebrafish when compared to zebrafish not 
exposed to arsenic. In addition, miRNA-199 and control co-injected zebrafish displayed 
decreased bacterial burden when compared to control zebrafish. Conversely, zebrafish 
co-injected with CFTR and miRNA-199 MOs resulted in an increased burden when 
compared to fish co-injected with CFTR and control MOs. These results appear to be in 
disagreement and suggest a role for miRNA-199 in CFTR KD zebrafish, but to fully 
elucidate this role more studies must be conducted.  
 In addition to the bacterial burden experiments, a respiratory burst assay was 
conducted to understand the role of miRNA-199 during infection and arsenic exposure in 
CFTR KD zebrafish. As expected, we saw that arsenic exposure decreased the overall 
respiratory burst and CFTR KD also decreased respiratory burst as previously described 
(147, 177). Similar to the results shown in Figure A.2., Figure 2.5. shows that zebrafish 
co-injected with miRNA-199 and control MO had a dampened ROS production when 
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compared to control zebrafish. This result confirms the results of Gagne and Sullivan et 
al. Conversely, in the context of CFTR the opposite results are true. In zebrafish co-
injected with CFTR and control MOs and zebrafish co-injected with control and miRNA-
199 MOs both had dampened respiratory bursts when compared to zebrafish co-injected 
with CFTR and miRNA-199 MOs. This result is also shown in Figure A.2. and was not 
an expected outcome. In fact, there are many current strategies being studied to modulate 
the PMN-mediated inflammation, which has been correlated with decreased lung 
function (112, 194-197). Modulation of inflammation via miRNA-199 KD in our 
experiments, in which it was expected that ROS production would decrease, actually led 
to an increase in ROS production and a trend toward increased bacterial burden. 
Therefore, there appears to be a novel role for CFTR and miRNA-199 KD that leads to 
both an increased bacterial burden and respiratory burst. CF patients from an early age 
had decreased iNOS expression, which has been implicated in reduced bacterial clearance 
(27, 116, 117, 119). Potentially, the further decrease in NO- could be leading to an 
increased bacterial burden, which in turn is leading to an increased immune response and 
subsequently an increase in ROS. 
 In conclusion, a potential role for miRNA-199 in regulating the production of 
ROS and aiding in the reduction of the bacterial burden in control fish has been 
established. Although, the data from the bacterial burden experiments were not 
significant, a trend is suggested that is consistent with the RBA data, pointing to a 
potential role for miRNA-199 in protecting zebrafish from infection by innate immune 
regulation. More biological replicates of the bacterial burden assay would be necessary 
before any conclusions about a role miRNA-199 might have in overall bacterial 
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concentration could be made, but it is clear that miRNA-199 has a significant role in the 
production of ROS. In addition, it has become apparent that zebrafish co-injected with 
CFTR and miRNA-199 MOs display increased burden and ROS production, which was 
not an expected result. Additional research is necessary to understand why miRNA-199 
in conjunction with CFTR KD is increasing respiratory burst and potentially increasing 
bacterial burden.  
 Future experiments must include repeating the bacterial burden experiment to 
account for the high degree of variability found within the three biological replicates. In 
addition, overexpression of miRNA-199 could be performed, followed by a survival 
study, bacterial burden, and respiratory burst assay. If during overexpression of miRNA-
199 decreased bacterial burden and/or respiratory burst was observed in CFTR KD 
zebrafish it will help to both validate our current results and aid us in understanding why 
miRNA-199/CFTR KD zebrafish display an increased bacterial burden and respiratory 
burst.  
 miRNA-199 is a highly conserved miRNA in zebrafish and humans and its targets 
have been shown to be involved in regulation of the metabolic process, regulation of 
signaling, cell communication, signal transduction, and response to stimulus (190, 191, 
198). This suggests that miRNA-199 is involved in many area of biology and in future 
experiments its targets could be knocked-down in zebrafish to understand their 
relationship to miRNA-199. In addition, following a KD or overexpression of miRNA-
199 a RNA-Seq experiment could be conducted and the dysregulation of protein-coding 
genes along with ncRNA could be analyzed. These experiments could help to further 
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elucidate targets of miRNA-199 and increase our understanding of its role in immunity 
and infection. 
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CHAPTER 3 
CANDIDATE LINCRNAs VALIDATE RNA-SEQ VIA RT-QPCR  
AND PLAY A ROLE ININFECTION BY P. AERUGINOSA  
3.1. Introduction 
 Cystic fibrosis (CF) is a lethal hereditary disease that is characterized by a 
mutation in both copies of the Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR), a chloride ion channel present in most epithelial cells and a variety of other cell 
types. The most common form of this disease is the deletion of a phenylalanine amino 
acid at position 508 termed ΔF508, which accounts for roughly 70% of cases worldwide 
and 90% of the cases in the United States. Although ΔF508 mutations make up the vast 
majority of CF cases, there are greater than 2000 other mutations that cause the disease 
known as CF (1, 199). These mutations lead to a multitude of different problems with the 
CFTR protein, but the end result is almost always the same, thick mucus formation. The 
thick, sticky mucus is formed as a result of improper ion trafficking due to the mutated 
chloride ion channel, which causes an assortment of issues in the gastrointestinal, 
endocrine, reproductive, and respiratory systems. Although CF is a multi-organ disorder, 
it is usually referred to as a lung disease because the overwhelming majority (>90%) of 
CF patients ultimately die from persistent lung infection (1, 23).   
 The most prevalent microorganism in adults with CF is Pseudomonas aeruginosa, 
a gram-negative, opportunistic, and ubiquitous pathogen that employs an arsenal of 
devastating virulence factors. Among these virulence factors is the quorum sensing (QS) 
system that is crucial in the production of virulence factors through multicomponent 
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communication and regulatory networks. The QS system is responsible for the production 
of biofilms, which give P. aeruginosa increased resistance to opsonization, destruction, 
and antibiotic therapies (41, 42, 46, 47). P. aeruginosa is also known to adapt to host 
pressures and evolve to a mucoid form, which is responsible for the chronic lung 
infections and is largely blamed for its lethality (53). 
 In addition to P. aeruginosa, environmental factors such as arsenic have been 
recently studied as a confounding factor to the health of individuals living with CF. 
Arsenic has been shown to reduce the respiratory burst of immune cells in response to 
viral and bacterial infection in zebrafish (Danio rerio) while at the same time increasing 
the release of antiviral and antibacterial cytokines (147). Interestingly, arsenic has also 
been connected to c-Cbl-mediated ubiquitination and degradation of CFTR in the human 
lung (149). ). Furthermore, arsenic concentration in well water in Bangladesh has been 
correlated with higher than normal sweat conductivity in non-CF patients (151). Arsenic 
is a complicating factor in the already difficult CF puzzle. 
 Non-coding RNA (ncRNA), such as long intergenic non-coding RNAs 
(lincRNA), have been implicated in CF, but little is known about their potential in 
therapeutics and CF research (152). lincRNAs are a member of the long non-coding RNA 
(lncRNA) family that are characterized by not being included in any part of other genes. 
lincRNAs function via a variety of proposed mechanisms including cotranscriptional 
regulation, regulation of gene expression, acting as molecular decoys, and acting as 
cytoplasmic scaffolds (153). Research has been conducted to catalog lincRNA loci and 
transcripts across a multitude of species including the zebrafish. Interestingly, lincRNA 
have been shown to be differentially expressed between CF and non-CF individuals with 
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many of the differentiated lincRNAs being related to inflammation in CF bronchial 
epithelium cells (152). It can be concluded that studies of lincRNA and its relationship 
with CF could give rise to novel therapies for CF. 
 In a search for ways to study the effect that these biological factors have on 
individuals with CF in vivo, the zebrafish is an attractive, viable test system. The 
zebrafish is an optically clear member of the teleost family of vertebrates that has become 
a powerful tool in the study of diseases and immunity due to its ease of breeding and 
infection, high fecundity, and relatively low cost. In addition, the zebrafish is 
genomically and physiologically similar to humans and depends solely on an innate 
immune system for the first 4-6 weeks of life (172, 174, 175). Importantly, the zebrafish 
is an excellent model for the study CF and P. aeruginosa infection (177). During CFTR 
knockdown (KD) using a morpholino oligonucleotide (MO) the zebrafish displayed a 
dampened respiratory burst and decreased bacterial burden (177). 
 RNA-Sequencing analysis elucidated the expression profile of ncRNA by 
environmental interactions in innate immunity (Figure 2.1.). Zebrafish were injected with 
MO at the 1-cell stage with either 2.5 ng of a co-injection mixture of two CFTR MO or 
2.5 ng of control MO. Arsenic was added to the egg water at a concentration of 0, 2, or 
10 parts per billion (ppb) and changed daily with the egg water. At 48 hours post 
fertilization (hpf) the zebrafish were injected with 50 CFU/embryo of P. aeruginosa into 
the Duct of Cuvier (DC). At 6 hours post infection (hpi) the zebrafish were homogenized 
and RNA was isolated for RNA-Seq.  
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Figure 3.1. Proposed mechanisms for lincRNA function. lincRNAs are 
thought to function in many different ways including cotranscriptional 
regulation by either interacting with factors or transcribing through a 
regulatory region, the cis or trans regulation of gene expression, interaction 
with RNA-binding factors, or initiating posttranscriptional regulation via 
binding with other RNA transcripts. In addition, there are believed to be 
more functions that have yet to be discovered. Adapted from: Ulitsky I, 
Bartel DP. 2013. lincRNAs: genomics, evolution, and mechanisms. Cell 
154:26-46. 
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 The resulting RNA-Seq reads were aligned to lincRNAs annotated from three 
recent studies of zebrafish lincRNAs and their loci, and several candidate lincRNA were 
elucidated (161, 169, 170). The lincRNA of interest were differentially expressed when 
zebrafish were infected with P. aeruginosa. To validate the RNA-Seq data, an identical 
experiment was run to mirror the P. aeruginosa infection from the RNA-Seq experiment. 
Zebrafish were infected with P. aeruginosa at 48 hpf and RNA was collected at 3, 6, and 
9 hpi. The RNA was then converted to cDNA and qPCR was performed. Initially a panel 
of inflammatory cytokines was profiled to confirm innate immune response to P. 
aeruginosa, which resulted in a strong, significant upregulation in all cytokines assayed 
across the majority of timepoints. Next, the expression of the candidate lincRNAs, all of 
which are not characterized in any species, was measured. Linc-mettl3 was found to be 
significantly upregulated at 3 hpi but not at 6 hpi, which did not corroborate the RNA-
Seq data. Although linc-mettl3 did not validate the RNA-Seq data, linc-cyb5a and linc-
zgc:113057_2 showed statistically significant trends that mirrored the RNA-Seq data. 
Interestingly, linc-zgc:113057_2 was found to have increased almost 34-fold in the qPCR 
analysis, which is an approximately 32 fold increase compared to the RNA-Seq data. 
Furthermore, it was found that linc-zgc:113057_2 has a neighboring protein coding gene, 
zgc:113057, which is differentially expressed at 3 and 9 hpi. These findings help to not 
only validate the RNA-Seq data, but also to our knowledge this is the first time that 
lincRNAs have been shown to be modulated during bacterial infection in zebrafish and 
among only a few in other animal models. There is no cure for CF and bacterial 
infections are still difficult to control, but these results inform new hypotheses for future 
experiments that could potentially produce novel CF treatments and bacterial therapies.   
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3.2. Materials and methods 
 3.2.1. Zebrafish care and maintenance 
 The zebrafish were maintained in agreement with the guidelines established by 
the University of Maine Institutional Animal Care and Use Committee (IACUC). 
Zebrafish embryos were collected at the one-cell stage of development from natural 
spawns of adult AB zebrafish. They were kept at 28 ̊C on a 16 hour light and 8 hour dark 
cycle. The zebrafish were grown in egg water (60 mg/L Instant Ocean sea salts), which 
was changed daily. Deceased zebrafish were collected with a plastic pipette and disposed 
of daily. Unused zebrafish, along with all fish at the end of each experiment, were 
euthanized by immersion in a lethal dose of tricaine followed by proper disposal.  
 3.2.2. Bacterial preparation 
 P. aeruginosa strain PA14 (p67T1) was used for all infections (Singer et al., 
2010). PA14 (p67T1) contains a constitutive plasmid-encoded RFP variant of d-Tomato, 
which was engineered by (192). Bacterial colonies were grown on 15 g/L bacteriological 
agar (Affymetrix, Cleveland, OH) combined with 25 g/L LB (Affymetrix, Cleveland, 
OH) supplemented with 750 µg of ampicillin/mL (Sigma-Aldrich, St. Louis, MO). Two 
days prior to infection bacteria were streaked out on the aforementioned plates and grown 
for 24 hours at 37 ̊C. The night before the infection experiment a single colony was 
picked using a p200 micropipettor tip and placed in a glass test tube containing 4 mL of 
25 g/L LB broth (Affymetrix, Cleveland, OH) supplemented with 750 µg of 
ampicillin/mL (Sigma-Aldrich, St. Louis, MO). The test tube was placed in a shaking 
incubator (250 rpm) for 12-16 hours at 37 ̊C. The following morning a sample of the 
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bacterial culture was diluted 1:20 in a 1 mL cuvette with PBS (Life Technologies, Grand 
Island, NY) and measured using a spectrometer at 600 nm. An OD of 1 was added to 25 
mL of 25 g/L LB (Affymetrix, Cleveland, OH) supplemented with 750 µg of 
ampicillin/mL (Sigma-Aldrich, St. Louis, MO) in a 125 mL Erlenmeyer flask and placed 
on a shaking incubator (250 rpm) for 2-4 hours. The culture was then added to a 50 mL 
plastic conical tube and centrifuged at 5000 x g for 5 min at 4 C̊. The supernatant was 
decanted and the pellet was resuspended and washed in 3 ml of PBS (Life Technologies, 
Grand Island, NY). This step was repeated 3 times and was then resuspended in 2 mL of 
PBS (Life Technologies, Grand Island, NY). The culture was then decanted into a 5 mL 
syringe (BD, Franklin Lakes, NJ) connected to a 30 gauge x 1/2 needle (0.3 mm x 13 
mm) (BD, Franklin Lakes, NJ) and expelled into a sterile 15 mL conical tube. This step 
was repeated twice. 50 µL of the bacterial culture was diluted 20x into 950 µL of PBS 
(Life Technologies, Grand Island, NY) into a clear plastic cuvette. The cuvette was read 
at 600 nm in a spectrophotometer. Bacterial cultures were diluted in PBS (Life 
Technologies, Grand Island, NY) and 50 µL of 5% phenol red (PR) (Sigma-Aldrich, St. 
Louis, MO) to achieve a 50 CFU/embryo injection. PR was used to visualize the injection 
into the embryo. 
 3.2.3. Bacterial injection 
 The zebrafish were dechorionated manually using style 5 Dumont tweezers 
(Electron Microscopy Sciences, Hatfield, PA) at 2 days post fertilization (2dpf). Embryos 
were then anesthetized in 4 mg/mL Tricaine solution (Western Chemical, Ferndale, WA) 
and lined up on a 3% agar gel petri dish. P. aeruginosa was then injected into the 
embryo’s Duct of Cuvier with 3 nL of P. aeruginosa strain PA14 (p67T1) to a final 
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concentration of 50 CFU/embryo. The LD50 of PA14 (p67T1) was determined previously 
to be 50 CFU/embryo. This concentration resulted in 50% mortality by 48 hpi (177). 
Injection was done using a MPPI-2 microinjection apparatus (Applied Scientific 
Instruments, Eugene, OR) using pulled microcapillary needles (Sutter Instruments, 
Novato, CA). All embryos were screened with a Zeiss fluorescence screening microscope 
(Carl Zeiss AG, Oberkochen, Germany) for Texas Red fluorescence. Any embryos that 
were improperly injected and did not fluoresce red were removed and euthanized 
according to IACUC protocol with a lethal dose of Tricaine (Western Chemical, 
Ferndale, WA).  Post injection, the zebrafish embryos were maintained at 28 ̊C. 
 3.2.4. RT-qPCR primer design 
 Primers of candidate lincRNAs were designed using Integrated DNA 
Technologies (IDT) PrimerQuest Tool. Primers were diluted to 10 µM. The sequences 
are listed in Table 3.1. 
Table 3.1. RT-qPCR lincRNA primers 
Primer 
Name  
Forward Sequence Reverse Sequence 
linc-mettl3 AGAAGATCCTCTGCGCTTTAC CTTCACTCACTACAGCAGTC
TC 
linc-
zgc:158317 
AGTTCATGTTAGAGCAGGTAC
AA 
GACTTGCAGCAACCAATACA
C 
zgc:113057_2 GGACTGTGCATTCTGGGTAATC CCTTCTGATGCCTTTGCTTTG 
linc-cyb5a GACGAGTGACAGAGAACATCA
A 
CACAGACCAAACAAACCAA
GAG 
linc-
loc555288 
CATCGCCACTCAGACAATCA TCCAGAACAACTTCACCTAC
AC 
linc-
zgc:113057_2 
CATTCAGATCATCCTCAGATCC
C 
GTACTGGCTCACTGTCTTGTT 
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 3.2.5. RT-qPCR 
 Total RNA was isolated from infected embryos at 3, 6, and 9 hours post infection 
(hpi). Ten fish per treatment were homogenized in a Bullet Blender (Next Advance, 
Averille Park, NY)  in 200 µL Trizol (Thermo Fisher Scientific, Waltham, MA) in 
separate 1.5 mL microcentrifuge tubes containing two 3.5 mm stainless steel beads (Next 
Advance, Averille Park, NY). All treatment groups were prepared in triplicate. RNA was 
isolated using the Direct-Zol Miniprep Plus kit (Zymo Research, Irvine, CA). RNA was 
then converted into cDNA via the iScript Reverse Transcriptase Supermix for RT-qPCR 
kit (Bio Rad, Hercules, CA). The cDNA synthesis was performed with 500 µg of RNA 
sample per replicate. After the conclusion of the cDNA synthesis the samples were 
diluted with 180 µL of nuclease-free water. RT-qPCR was done utilizing PerfeCTa 
SYBR Green FastMix (Quanta Biosciences, Gaithersburg, MD). RT-qPCR was 
performed with a CFX96 Real-Time System (Bio Rad, Hercules, CA). Error bars 
represent SEM. The data represent three independent trials and statistical significance 
was determined by an unpaired t test (GraphPad Prism 6, La Jolla, CA). 
3.3. Results 
 3.3.1. Determination of candidate lincRNAs from RNA-Seq data 
 The expression of lincRNAs was examined by aligning RNA-Seq reads to 
catalogs of lincRNA loci (161, 169, 170). This present study focused on the differential 
expression of zebrafish lincRNAs in fish infected with P. aeruginosa alone, i.e. without 
cftr KD or arsenic exposure. This subset of the RNA-Seq was examined to elucidate 
lincRNAs that play a role in infection in order to find potential targets for improving P. 
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aeruginosa clearance. The loci elucidated from the three references listed were cross 
referenced with the RNA-Seq data, and a small subset of the lincRNAs showed 
significant dysregulation during P. aeruginosa infection, including: linc-mettl3, linc-
zgc:113057_2, linc-zgc:158317, linc-cyb5a, and linc-loc555288 (Figure 3.2a.). These 
genes were chosen based on their strong log2 fold change and a P value and discovery 
rate (FDR) below the 0.05 threshold (Figure 3.2b.). 
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Figure 3.2. Five differentially expressed lincRNAs identified in zebrafish 
infected with 50 CFU/embryo at the 48 hpi. (a) A MA plot represents 
expression data of the lincRNAs found in Ulitsky et al. (169). Each dot 
represents a different lincRNA with the red dots representing lincRNAs that 
have a P value and FDR below 0.05. The plot displays the log2 fold change 
on the y-axis and the mean expression on the x-axis. (b) The lincRNA 
represented above as red dots are listed with their log2 fold change, P value, 
and FDR (false discovery rate). A P value and FDR below 0.05 is 
considered statistically significant.  
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3.3.2. Three candidate lincRNAs are found to be protein-coding genes and one is 
neighboring a lincRNA of interest. 
 After examining current gene annotations of two candidate lincRNAs using the 
University of California Santa Cruz (UCSC) Genome Browser (200), both linc-
zgc:158317 and linc-loc555288 were found to be protein-coding genes and were 
therefore removed from further consideration. linc-zgc:113057_2 was also determined to 
be a protein-coding gene named zgc:113057, which has a neighboring lincRNA called 
linc-zgc:113057_2 (Figure 3.2). Therefore, linc-zgc:113057_2 was kept as a candidate 
lincRNA with the corrected loci. In addition, it was found that linc-zgc:113057_2 is very 
strongly upregulated during P. aeruginosa infection when compared to PBS injected 
zebrafish. zgc:113057_2 was not found to be significantly dysregulated during P. 
aeruginosa infection.  
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Figure 3.3. The coordinates for linc-zgc:113057_2 taken from Ulitsky et al. 
were determined to yield a protein-coding gene named zgc:113057 (2011). 
A neighboring lincRNA, linc-zgc:113057_2 was found relatively close to 
zgc:113057 on chromosome 7 and was subsequently added to the list of 
candidate lincRNAs. In addition, in the second expression profile that linc-
zgc:113057_2 appears to be strongly differentially expressed during P. 
aeruginosa (labeled at PA above) infection when compared to the first row 
showing expression during a PBS injection (control). Zgc:113057 does not 
appear to be differentially regulated during P. aeruginosa infection. 
 3.3.3. Inflammatory cytokines are significantly and strongly upregulated 
during P. aeruginosa infection 
 After determination of candidate lincRNAs, zebrafish were infected with P. 
aeruginosa at 48 hpi to mirror the design of the RNA-seq bacterial injections. This was 
done to both validate the RNA-Seq expression data and to further characterize the 
candidate lincRNAs. To verify that the zebrafish were properly infected and displayed a 
characteristic innate immune response, a panel of inflammatory cytokines were profiled 
via RT-qPCR (Figure 3.4.). IL-1, Serum-amyloid A (SAA), CXCL8-L1, CXCL8-L2 
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(CXCL8-L1 and CXCL8-L2 are homologues in the zebrafish and are referred to as IL-8 
in humans), and tumor necrosis factor α (TNFα) were found and a characteristic 
expression profile was observed. All 5 of the cytokines displayed strong and significant 
upregulation of expression at 3, 6, and 9 hpi with the exception of CXCL8-L1. CXCL8-
L1did not have a significant change in expression at 9 hpi and, although still significant, 
it did not display a relatively large fold change at 6 hpi when compared to 3 hpi. The 
strong and significant upregulation of the inflammatory cytokines showed that a systemic 
bacterial infection was achieved. In addition, once the infection was confirmed, the 
expression of the candidate lincRNAs could be assayed. 
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Figure 3.4. A panel of inflammatory cytokines were significantly 
upregulated in response to P. aeruginosa infection. RT-qPCR was used to 
characterize the innate immune response of zebrafish embryos to P. 
aeruginosa infection at 6 hpi. All assayed cytokines showed statistically 
significant upregulation at 3 and 6 hpi, characteristic of the innate immune 
response to bacterial infection. All experiments are representative of 3 
biological replicates. Statistical analyses were performed with the unpaired 
t test. Error bars represent standard error of the mean. 
 
 3.3.4. Candidate lincRNAs validate RNA-Seq expression data 
 After the expression profile of inflammatory cytokines was shown to be 
characteristic of bacterial infection, the candidate lincRNAs were profiled via RT-qPCR 
(Figure 3.5.). linc-mettl3 was not significantly differentially expressed by RT-qPCR at 6 
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hpi, but was found to trend toward downregulation, as was found in the RNA-Seq data. In 
addition, linc-mettl3 was significantly increased at 3 hpi during P. aeruginosa infection, 
which was contrary to the RNA-Seq data. linc-cyb5a was significantly increased at 6 hpi 
during infection, with a fold change nearly identical to the RNA-Seq fold change. Lastly, 
linc-zgc:113057_2 was found to be very strongly upregulated at 3, 6, and 9 hpi, with a 
greater that 30-fold increase over PBS injection.  
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Figure 3.5. Candidate lincRNAs show disregulation consistent with RNA-
Seq. Wild-type zebrafish embryos were infection with 50 CFU/embryo of 
P. aeruginosa at 48 hpi. RNA was isolated at 3, 6. and 9 hpi and then 
converted to cDNA. RT-qPCR was run to assay the relative expression of 
the candidate lincRNAs in relation to the RNA-Seq data. (a) linc-mettl3 
displays a trend toward downregulation during P. aeruginosa infection but 
this is not significant. In addition, linc-mettl3 is showing the opposite trend 
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at 3 hpi. (b) linc-cyb5a shows a significant decrease in expression during 
infection at 6 hpi with a log fold change that is similar to the RNA-Seq log 
fold change. (c) linc-zgc:113057_2 expression is very strongly upregulated 
during infection, with a greater than 30-fold induction at 6 hpi. (d) A table 
showing the log fold change of the RNA-Seq alongside the qPCR log fold 
change. All experiments are representative of 3 biological replicates. 
Statistical analyses were performed with the unpaired t test. Error bars 
represent standard error of the mean. 
3.4. Discussion 
 Expression patterns of lincRNAs previously annotated by Ulitsky et al, Pauli et al, 
and Kaushik et al. from the RNA-Seq experiment were analyzed to investigate their 
potential roles in the innate immune response (161, 169, 170). We plotted the expression 
data from the RNA-Seq experiment using an MA plot and thresholds for P values and 
FDR, and found five lincRNAs that were differentially expressed during P. aeruginosa 
infection. Three of the candidate lincRNAs were found to be protein-coding genes. One 
was found to be the protein-coding gene zgc:113057, which interestingly had a 
neighboring lincRNA called linc-zgc:113057_2. We subsequently added the newly 
discovered lincRNA to our list of candidate lincRNAs.  
 The fact that these two genes of similar name are located relatively close to each 
other on chromosome 7 is interesting and generates new hypotheses for future studies. It 
would be interesting to determine if linc-zgc:113057_2 is acting as a promoter or co-
transcriptional regulator of zgc:113057, which is one of the many potential functions of 
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lincRNAs (153). It may also prove to be beneficial to find a protein-coding gene with 
which lincRNAs are associated, since lincRNAs are not well conserved from species to 
species. This fact makes it difficult to predict that a specific lincRNA in one species will 
have a similar function or even be present in another species. Although this may be the 
case for the lincRNAs of interest here, the function of lincRNAs, rather than their 
sequence or identity, is more likely to be conserved. Therefore, it may be beneficial to 
show a relationship between a lincRNA and protein-coding gene, because the protein-
coding gene is more likely to be conserved (153, 201). In addition, if a relationship 
between a lincRNA and protein-coding gene can be established it would make it easier to 
locate a homolog of the lincRNA in another species if the protein-coding gene were to be 
located first. 
  To validate the RNA-Seq expression data we aimed to duplicate the P. 
aeruginosa infection portion of the RNA-Seq experiment. To make sure that we 
produced a proper systemic infection we performed RT-qPCR on a panel of 
inflammatory cytokines including IL-1, SAA, CXCL8-L1, CXCL8-L2, and TNFα. These 
cytokines are important in the initial innate immune response to bacterial infection and 
were all shown to be strongly upregulated in our study at the 6 hpi timepoint, as expected 
(108, 147, 202, 203). The reduction of CXCL8-L1 expression was also expected as 
CXCL8-L1 is known to be an early marker of bacterial infection, since it is involved in 
neutrophil chemotaxis. In CF patients it is known to be consistently upregulated and 
therefore yields chronic inflammation and neutrophil presence, but in non-CF individuals 
CXCL8-L1 should eventually decrease after bacterial clearance to maintain proper 
inflammation levels (6). In addition, CXCL8-L1 may be decreased at 6 and 9 hpi because 
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its homologue, CXCL8-l2 is more actively upregulated at that time instead of CXCL8-
L1. No matter the case, the significant upregulation of the inflammatory cytokines at 6 
hpi was measured as expected, confirming the presence of systemic infection in the 
zebrafish embryos.  
 Candidate lincRNAs showed significant differential expression at 6 hpi during P. 
aeruginosa infection when compared to PBS injections. linc-mettl3 displayed a trend 
toward downregulation at 6 hpi, but this failed to be statistically significant. linc-cyb5a 
was significantly downregulated during P. aeruginosa infection and yielded a log fold 
change that was nearly identical to the RNA-Seq expression data. In addition, linc-
zgc:113057_2 was significantly dysregulated at 6 hpi with a greater than 30-fold 
induction in P. aeruginosa-infected zebrafish compared to control zebrafish. These data 
are exciting because they not only validate the RNA-Seq but they also show a fold-
induction greater than expected. This is particularly interesting because linc-RNAs are 
known for being expressed at very low levels (163, 164). The highest significant 
expression of lincRNA in the RNA-Seq was linc-zgc:113057_2 with a 2.4 log fold 
increase over controls. Our finding of a 32-log fold increase of linc-zgc:113057_2 during 
infection is exciting as it suggests that this is playing a key role in immunity and could 
potentially lead to improved bacterial therapies.  
 To further elucidate the function of linc-zgc:113057_2, its expression can be 
knocked down in the zebrafish prior to challenging the zebrafish with P. aeruginosa 
infection. By utilizing locked nucleic acid (LNA) technology (Exiqon, MD) we can KD 
linc-zgc:113057_2 and begin to characterize its function. After KD, RNA can be isolated 
for RT-qPCR analysis and linc-zgc:113057_2 KD can be confirmed. In addition, an 
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expression profile of cytokines can be analyzed to determine linc-zgc:113057_2 
involvement in regulation of cytokine expression. Furthermore, a bacterial burden and 
respiratory burst assay along with a zebrafish survival experiment could be performed to 
understand if linc-zgc:113057_2 has a direct effect on bacterial burden, level of ROS, and 
zebrafish survival. Moreover, linc-zgc:113057_2 can be overexpressed after generation 
of a clone and the same experiments can be performed. Lastly, an in situ hybridization 
(ISH) can be conducted to determine the spatial expression of linc-zgc:113057_2 in the 
zebrafish embryo. ISH labels DNA or RNA, allowing visualization of the target through 
the use of a complementary probe. 
 In conclusion, five lincRNAs were found to be differentially regulated during P. 
aeruginosa infection in zebrafish embryos in a large-scale RNA-Seq experiment. The 
RNA-Seq made use of three publications to determine the loci of the lincRNAs (161, 
169, 170). Three of the candidate lincRNAs were determined to be protein-coding, but 
one of them turned out to be zgc:113057, which had linc-zgc:113057_2 as a neighboring 
gene. This was interesting because lincRNA are known to act as regulators of protein-
coding genes and may prove to be useful in locating linc-zgc:113057_2 or a functional 
orthologue in other species (153, 201). To validate the RNA-Seq, we repeated the 
infection with P. aeruginosa in zebrafish embryos exactly parallel to the method used for 
the RNA-Seq. We found a characteristic upregulation of inflammatory cytokines in 
response to bacterial infection. Furthermore, we validated the RNA-Seq expression data 
with linc-cyb5a and linc-zgc:113057_2 having statistically significant differential 
expression at 6 hpi. In addition, we found linc-zgc:113057_2 to be more strongly 
upregulated than previously expected and plan to characterize its function in infection 
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and immunity. We suggest a series of experiments after KD or overexpression of linc-
zgc:113057_2 followed by P. aeruginosa infection in zebrafish embryos. 
 In the early 2000s ncRNA were considered to be junk with no function, but now 
we are showing here that lincRNAs are being dysregulated during bacterial infection and 
miRNAs play a role in modulating the respiratory burst response to infection in CFTR 
morphant zebrafish. It is known that CF is incurable and CF patients have an average life 
expectancy of only 37 years, which is mostly due to uncontrollable, chronic bacterial 
infections. Therefore, it is important to continue the discovery and elucidation of ncRNA 
and their role in immunity to aid in the development of novel therapies for bacterial 
infection and cystic fibrosis.  
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APPENDICES  
Appendix A.  
Raw bacterial burden data 
 
Figure A.1. Bacterial burden biological replicate 1. An increase in bacterial 
burden is observed in the zebrafish coinjected with control and miRNA-199 
MOs compared to control fish. This is the opposite trend that is seen in 
Figure A.2. between these two experimental groups. These data were 
analyzed via ANOVA 4-factor analysis using JMP 8.01 (SAS, Cary, NC). 
 
 
 
103 
 
 
 
Table A.1. Bacterial burden biological replicate 1 raw data 
 
Table A.2. Bacterial burden biological replicate 1 least square mean raw 
data 
 
 
0,CT,CT 20 120 11 292 132 78 0 50 8 2 25 1 28 408 7 112 168 49 280 352
0,CFTR,CT 44 6 18 37 4 37 58 14 27 13 39 13 27 29 17 5 6 7 508 276
0,CT,miR 20 44 36 15 300 35 5 21 9 9 13 5 3 10 84 9 11 23 25 8
0,CFTR,miR 70 146 16 10 13 308 3 384 12 126 32 148 67 26 68 16 8 40 16 17
10,CT,CT 44 1312 116 232 18 13 824 216 10 308 544 312 54 87 13 33 95 304 6
10,CFTR,CT 8 172 60 332 31 70 296 14 3 1192 90 139 212 122 436 68 168 78
10,CT,miR 384 12 192 412 39 119 76 360 61 14 272 16 340 118 248 300 21 14 12
10,CFTR,miR 97 33 15 11 144 0 34 80 24 200 15 118 11 19 47 110 17 4 96 66
Group Least Sq Mean Std Error
0,CT,CT 5.278726 0.441538
0,CT,CFTR 4.6140099 0.441538
0,CT,miR 6.5253556 0.453008
0,CFTR,miR 6.5159433 0.465422
10,CT,CT 4.1904388 0.441538
10,CT,CFTR 5.2169868 0.441538
10,CT,miR 6.3775371 0.453008
10,CFTR,miR 5.0285014 0.441538
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Figure A.2. Bacterial burden biological replicate 2. Arsenic was shown to 
increase the bacterial burden in zebrafish when compared to zebrafish not 
exposed to arsenic. In addition, miRNA-199 and control coinjected 
zebrafish displayed a decreased bacterial burden when compared to control 
zebrafish. Conversely, zebrafish coinjected with CFTR and miRNA-199 
MOs resulted in an increased burden when compared to fish coinjected with 
CFTR and control MOs. These data were analyzed via ANOVA 4-factor 
analysis using JMP 8.01 (SAS, Cary, NC). 
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Table A.3. Bacterial burden biological replicate 2 raw data 
 
Table A.4. Bacterial burden biological replicate 2 least square mean raw 
data 
 
 
 
0,CT,CT 15 189 2 7 8 7 2 38 4 11 45 7 3 2 5 46 1 3 3 12
0,CFTR,CT 1 107 1 32 4 6 6 2 6 5 1 5 67 12 7 208 1 7 11 8
0,CT,miR 120 10 9 3 322 186 26 174 97 432 480 182 148 15 16 272 248 230 1 14
0,CFTR,miR 240 54 182 107 138 29 4 4 1 1 1 1 2 4 1 1 3 2 1 1
10,CT,CT 6 24 0 13 142 2 3 2 30 2 21 9 5 7 127 82 1 2 5 17
10,CFTR,CT 5 88 24 3 18 1 4 82 1 1 5 3 2 27 14 1 1 5 2 300
10,CT,miR 24 160 1 1 1 10 1 35 1 1 43 1 1 1 1 6 13 169 211 153
10,CFTR,miR 30 7 8 57 210 1 300 400 5 96 62 280 1 56 200 46 1 63 106 50
Group Least Sq Mean Std Error
0,CT,CT 3.2025257 0.503432
0,CT,CFTR 3.1774156 0.503432
0,CT,miR 3.3204366 0.503432
0,CFTR,miR 3.0468581 0.503432
10,CT,CT 5.9852581 0.503432
10,CT,CFTR 3.0063189 0.503432
10,CT,miR 3.2541185 0.503432
10,CFTR,miR 5.2666642 0.503432
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Figure A.3. Bacterial burden biological replicate 3. No significance was 
observed when analyzing biological replicate 3. These data were analyzed 
via ANOVA 4-factor analysis using JMP 8.01 (SAS, Cary, NC). 
Table A.5. Bacterial burden biological replicate 3 raw data 
 
 
 
 
 
 
0,CT,CT 2 57 12 1 2 6 3 15 87 2 1 3 5 8 2 15 38 2 30 24
0,CFTR,CT 3 76 110 3 4 17 128 2 3 2 56 4 1 2 15 6 76 94 16 2
0,CT,miR 2 3 14 1 2 26 23 8 35 11 6 3 10 3 5 2 1 6 1 9
0,CFTR,miR 1 2 2 3 1 2 1 2 2 67 216 8 1 2 6 1 20 27 2 1
10,CT,CT 104 2 1 47 1 2 64 9 2 57 118 18 83 99 94 60 7 4 2 68
10,CFTR,CT 2 1 186 2 2 3 3 10 9 3 4 9 5 6 2 2 66 288 36 73
10,CT,miR 5 2 4 1 2 5 2 6 2 34 3 4 9 3 3 52 27 2 41 1
10,CFTR,miR 7 2 4 2 1 2 3 2 41 101 17 129 30 290 2 2 2 2 2 2
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Table A.6. Bacterial burden biological replicate 3 least square mean raw data 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Least Sq Mean Std Error
0,CT,CT 3.0694181 0.429451
0,CT,CFTR 3.5895205 0.429451
0,CT,miR 4.197565 0.429451
0,CFTR,miR 3.2974581 0.429451
10,CT,CT 2.6953736 0.429451
10,CT,CFTR 2.4060352 0.429451
10,CT,miR 2.6462376 0.429451
10,CFTR,miR 3.028383 0.429451
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Appendix B. 
Raw respiratory burst data 
Table B.1. Respiratory burst assay biological replicate 1 raw data. 
 
Table B.2. Respiratory burst assay biological replicate 1 least square mean raw data. 
 
 
 
0,CT,CT 0,CFTR,CT 0,CT,miR 0,CFTR,miR 10,CT,CT 10,CFTR,CT 10,CT,miR 10,CFTR,miR
134721 84508 138261 143439 131124 112946 95291 136231
123465 82189 129472 135356 135125 133804 129927 117730
116588 99336 147343 121231 129091 130975 121075 117377
134192 96576 142755 146189 135014 128192 135623 121766
106956 81338 143733 124540 136830 130847 127883 136974
114055 93264 123389 1613 133927 136855 73484 130160
135102 97979 143793 126219 131473 139109 131148 130555
126116 80315 136104 109631 143511 138583 124739 135754
137023 88626 125708 143123 141987 128371 85426 108415
131532 93985 136948 128091 137406 127645 135901 127725
128319 84471 137844 149378 129603 128891 127296 112935
140731 58900 158429 109285 143778 116239 126882 102640
127476 90692
135134 11898
108856 87830
120626 88010
Group Least Sq Mean Std Error
0,CT,CT 126305.75 4693.446
0,CT,CFTR 82494.81 4693.446
0,CT,miR 138648.25 5419.524
0,CFTR,miR 119841.25 5419.524
10,CT,CT 135739.08 5419.524
10,CT,CFTR 129371.42 5419.524
10,CT,miR 117889.58 5419.524
10,CFTR,miR 123188.5 5419.524
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Table B.3. Respiratory burst assay biological replicate 2 raw data. 
 
Table B.4. Respiratory burst assay biological replicate 2 least square mean raw data. 
 
 
 
 
 
 
0,CT,CT 0,CFTR,CT 0,CT,miR 0,CFTR,miR 10,CT,CT 10,CFTR,CT 10,CT,miR 10,CFTR,miR
71235 7189 60837 63205 17839 852 73744 63964
64499 56109 71949 65950 56500 69401 64921 58955
62532 55431 54116 66778 58571 76043 32767 63156
68561 64050 50882 62370 68245 69389 69239 78818
56671 65181 66801 64536 56918 48063 70991 49031
62053 60991 57949 37954 62005 64592 80208 68162
60345 65716 115710 80979 51211 21084 73106 71056
60508 69649 33726 6013 51996 12537 76862 73345
59806 58005 106515 9191 61156 64909 72212 59835
43865 62237 95554 26809 64733 84089 65737 66240
56875 51861 26105 27570 61649 4027 59681 70548
63469 59221 21104 12488 66411 5524 70110 68060
Group Least Sq Mean Std Error
0,CT,CT 60868.25 5895.511
0,CT,CFTR 56303.333 5895.511
0,CT,miR 63437.333 5895.511
0,CFTR,miR 43653.583 5895.511
10,CT,CT 56436.167 5895.511
10,CT,CFTR 43375.833 5895.511
10,CT,miR 67464.833 5895.511
10,CFTR,miR 65930.833 5895.511
110 
 
 
 
Table B.5. Respiratory burst assay biological replicate 3 raw data. 
 
Table B.6. Respiratory burst assay biological replicate 3 least square mean raw data. 
 
 
 
 
 
 
0,CT,CT 0,CFTR,CT 0,CT,miR 0,CFTR,miR 10,CT,CT 10,CFTR,CT 10,CT,miR 10,CFTR,miR
180803 21327 138197 63256 133040 129374 24269 180509
134591 127123 154383 145717 96481 76754 22668 146907
126025 127807 159530 144293 120288 23351 46633 10690
156758 135317 140634 144390 144969 16230 13110 147678
148337 44839 138043 174428 149802 22334 11290 155253
148327 55349 179605 142388 115499 69404 28943 180123
116703 85724 55481 49273 101361 12411 18283 115823
133000 152302 68361 33275 110242 83681 41890 148906
157502 20997 78982 147260 56286 136164
155110 56580 138723 88983
155869 171110
150821 109048
Group Least Sq Mean Std Error
0,CT,CT 146987.17 11433.66
0,CT,CFTR 93723.5 14003.31
0,CT,miR 117247.89 13202.45
0,CFTR,miR 103258.2 12524.94
10,CT,CT 128151.92 11433.66
10,CT,CFTR 54425 13202.45
10,CT,miR 25885.75 14003.31
10,CFTR,miR 131103.6 12524.94
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Appendix C. 
Raw RT-qPCR Cq data  
Table C.1. 18s RNA raw Cq values 
 
 
Time (hpi) P.a. or PBS injected Replicate #1 Cq Replicate #2 Cq Replicate #3 Cq
3 PBS 22.57 23.01 23.88
3 PBS 22.22 22.68 21.28
3 PBS 21.91 22.36 23.03
3 PBS 21.74 23.08 21.74
3 PBS 21.86 22.75 21.21
6 PBS 22.37 22.23 22.20
6 PBS 22.76 22.60 21.95
6 PBS 24.20 22.35 20.92
6 PBS 23.84 22.17 21.19
6 PBS 22.28 21.94 21.64
9 PBS 22.54 23.10 21.92
9 PBS 23.03 24.04 21.39
9 PBS 21.89 22.35 21.99
9 PBS 21.93 22.35 20.82
9 PBS 26.16 23.78 22.55
3 P.a. 23.15 22.98 22.26
3 P.a. 23.02 22.33 21.20
3 P.a. 23.85 21.87 20.86
3 P.a. 23.19 21.60 20.98
3 P.a. 23.59 21.23 20.80
6 P.a. 22.88 24.53 21.44
6 P.a. 22.36 22.20 21.29
6 P.a. 22.42 22.29 22.15
6 P.a. 22.14 21.70 20.78
6 P.a. 22.39 25.79 22.08
9 P.a. 23.21 22.24 21.94
9 P.a. 22.99 22.76 21.02
9 P.a. 21.68 24.54 20.80
9 P.a. 21.82 22.18 21.38
9 P.a. 24.92 22.36 23.53
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Table C.2. IL-1 RNA raw Cq values 
 
 
 
 
Time (hpi) P.a. or PBS injected Replicate #1 Cq Replicate #2 Cq Replicate #3 Cq
3 PBS 32.32 31.20 30.28
3 PBS 32.29 30.60 30.32
3 PBS 31.09 30.56 31.32
3 PBS 32.21 30.18 31.70
3 PBS 31.45 31.17 31.19
6 PBS 32.61 34.04 31.34
6 PBS 33.24 31.77 32.03
6 PBS 34.15 32.16 31.11
6 PBS 33.02 30.56 31.50
6 PBS 32.59 32.61 35.09
9 PBS 32.20 32.57 30.81
9 PBS 35.00 32.59 30.09
9 PBS 33.08 32.69 30.09
9 PBS 33.63 33.00 31.53
9 PBS 35.71 34.73 33.27
3 P.a. 27.98 26.59 26.25
3 P.a. 28.27 26.89 25.93
3 P.a. 27.55 27.58 26.03
3 P.a. 28.64 26.64 27.34
3 P.a. 28.97 26.22 26.48
6 P.a. 30.04 31.07 28.45
6 P.a. 29.91 28.54 29.05
6 P.a. 29.13 27.30 27.72
6 P.a. 31.09 27.79 27.13
6 P.a. 29.65 37.12 30.01
9 P.a. 32.22 28.83 28.93
9 P.a. 28.47 27.37 28.76
9 P.a. 28.15 27.24 28.52
9 P.a. 28.53 28.55 28.56
9 P.a. 34.21 25.33 29.27
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Table C.3. CXCL8-L1 RNA raw Cq values 
 
 
 
 
Time (hpi) P.a. or PBS injected Replicate #1 Cq Replicate #2 Cq Replicate #3 Cq
3 PBS 25.86 28.63 29.22
3 PBS 25.98 28.89 28.24
3 PBS 26.02 28.49 28.42
3 PBS 26.11 27.32 28.68
3 PBS 26.64 28.25 28.03
6 PBS 26.40 28.71 29.22
6 PBS 26.98 28.14 28.24
6 PBS 27.95 28.37 28.42
6 PBS 27.80 28.15 28.68
6 PBS 27.56 27.95 28.03
9 PBS 25.36 28.31 28.46
9 PBS 26.94 28.91 28.27
9 PBS 25.68 29.05 28.37
9 PBS 25.87 27.93 28.18
9 PBS 27.14 28.67 30.68
3 P.a. 23.69 25.10 24.87
3 P.a. 30.04 24.64 24.98
3 P.a. 23.48 25.24 25.41
3 P.a. 24.66 24.36 24.98
3 P.a. 24.53 24.63 24.54
6 P.a. 24.74 26.16 26.61
6 P.a. 24.42 26.11 25.46
6 P.a. 25.60 25.70 26.30
6 P.a. 26.49 25.56 24.34
6 P.a. 25.39 26.71 27.52
9 P.a. 26.28 26.76 26.63
9 P.a. 22.82 25.38 26.57
9 P.a. 22.71 24.53 26.43
9 P.a. 23.14 25.60 26.84
9 P.a. 24.16 24.48 26.62
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Table C.4. CXCL8-L2 RNA raw Cq values 
 
 
 
 
Time (hpi) P.a. or PBS injected Replicate #1 Cq Replicate #2 Cq Replicate #3 Cq
3 PBS 31.52 32.38 31.82
3 PBS 30.74 31.02 31.56
3 PBS 28.85 32.03 31.69
3 PBS 30.88 31.61 31.98
3 PBS 30.02 32.37 31.81
6 PBS 30.31 32.02 31.60
6 PBS 31.29 31.36 34.32
6 PBS 32.33 32.68 32.10
6 PBS 31.15 32.50 32.67
6 PBS 31.35 32.69 33.22
9 PBS 31.99 32.23 31.65
9 PBS 32.84 33.70 32.01
9 PBS 31.66 32.30 32.36
9 PBS 30.61 32.20 31.03
9 PBS 35.19 32.18 35.77
3 P.a. 28.53 30.17 31.30
3 P.a. 28.29 30.02 31.09
3 P.a. 28.77 30.95 31.45
3 P.a. 28.52 30.77 31.49
3 P.a. 30.23 29.72 30.06
6 P.a. 25.35 28.71 29.69
6 P.a. 26.47 29.13 28.27
6 P.a. 26.21 28.28 28.43
6 P.a. 28.07 27.76 29.36
6 P.a. 26.43 30.33 31.34
9 P.a. 31.04 29.01 30.54
9 P.a. 27.06 30.41 29.40
9 P.a. 28.27 28.20 29.46
9 P.a. 28.04 27.47 30.00
9 P.a. 28.32 27.27 30.05
115 
 
 
 
Table C.5. SAA RNA raw Cq values 
 
 
 
 
Time (hpi) P.a. or PBS injected Replicate #1 Cq Replicate #2 Cq Replicate #3 Cq
3 PBS 34.33 31.49 33.91
3 PBS 33.92 32.61 30.02
3 PBS 31.90 34.08 31.47
3 PBS 31.95 29.62 29.60
3 PBS 32.87 30.87 30.35
6 PBS 34.48 34.08 30.17
6 PBS 34.78 33.10 31.25
6 PBS 35.64 30.76 29.64
6 PBS 35.27 32.63 31.21
6 PBS 36.06 35.38 29.32
9 PBS 36.87 31.58 31.37
9 PBS 36.26 35.33 30.85
9 PBS 34.28 30.74 31.21
9 PBS 34.57 31.46 29.12
9 PBS 35.49 35.36 34.37
3 P.a. 27.16 27.49 26.63
3 P.a. 27.09 26.20 27.12
3 P.a. 27.22 27.14 26.85
3 P.a. 28.94 26.78 26.63
3 P.a. 27.91 26.82 26.90
6 P.a. 26.48 26.13 26.61
6 P.a. 26.75 27.66 26.52
6 P.a. 26.47 26.40 26.76
6 P.a. 27.07 26.85 26.63
6 P.a. 26.37 33.90 26.55
9 P.a. 27.60 26.30 25.19
9 P.a. 26.37 25.81 26.55
9 P.a. 27.05 25.79 26.62
9 P.a. 26.54 25.38 27.65
9 P.a. 28.86 25.28 27.41
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Table C.6. TNFα RNA raw Cq values 
 
 
 
 
Time (hpi) P.a. or PBS injected Replicate #1 Cq Replicate #2 Cq Replicate #3 Cq
3 PBS 33.26 36.14 34.49
3 PBS 33.41 35.35 33.24
3 PBS 31.85 34.26 35.37
3 PBS 39.96 33.64 33.17
3 PBS 33.69 36.16 34.14
6 PBS 34.71 36.22 36.14
6 PBS 34.39 35.87 34.13
6 PBS 33.89 35.06 35.08
6 PBS 34.28 35.12 35.49
6 PBS 35.20 35.54 35.49
9 PBS 35.60 35.24 36.37
9 PBS 34.95 39.34 37.71
9 PBS 34.17 35.37 37.71
9 PBS 34.55 35.30 37.71
9 PBS 33.33 38.40 37.71
3 P.a. 29.44 30.51 30.51
3 P.a. 28.98 30.07 30.54
3 P.a. 28.30 30.23 30.69
3 P.a. 29.85 30.32 30.10
3 P.a. 27.43 29.47 30.09
6 P.a. 28.83 31.21 32.55
6 P.a. 29.69 31.75 29.75
6 P.a. 29.91 31.23 31.68
6 P.a. 30.48 31.47 29.81
6 P.a. 28.28 31.55 31.60
9 P.a. 33.43 29.58 31.12
9 P.a. 35.82 29.63 31.08
9 P.a. 30.30 29.04 30.08
9 P.a. 29.70 30.26 30.42
9 P.a. 31.71 30.02 32.27
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Table C.7. linc-mettl3 RNA raw Cq values 
 
 
 
 
Time (hpi) P.a. or PBS injected Replicate #1 Cq Replicate #2 Cq Replicate #3 Cq
3 PBS 28.99 28.89 27.16
3 PBS 28.80 28.15 26.61
3 PBS 28.23 28.06 27.34
3 PBS 29.01 28.43 28.33
3 PBS 28.48 28.64 27.43
6 PBS 28.88 28.19 26.60
6 PBS 29.34 28.37 27.06
6 PBS 29.40 28.31 26.69
6 PBS 29.06 28.04 25.14
6 PBS 28.18 27.70 32.34
9 PBS 28.32 27.94 27.03
9 PBS 29.94 28.94 26.07
9 PBS 28.18 27.93 26.07
9 PBS 27.40 27.59 26.30
9 PBS 29.17 28.53 28.15
3 P.a. 28.03 27.17 25.59
3 P.a. 29.06 27.28 24.87
3 P.a. 28.99 28.34 25.85
3 P.a. 29.04 27.36 27.23
3 P.a. 29.47 25.62 27.06
6 P.a. 27.04 28.82 26.37
6 P.a. 28.02 27.44 27.45
6 P.a. 27.71 26.71 25.50
6 P.a. 28.49 27.31 24.61
6 P.a. 27.55 35.69 27.47
9 P.a. 30.22 27.63 27.23
9 P.a. 26.29 25.62 25.73
9 P.a. 26.91 26.98 25.22
9 P.a. 26.29 26.52 26.66
9 P.a. 32.03 25.07 28.93
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Table C.8. linc-cyb5a RNA raw Cq values 
 
 
 
 
Time (hpi) P.a. or PBS injected Replicate #1 Cq Replicate #2 Cq Replicate #3 Cq
3 PBS 29.15 28.84 31.57
3 PBS 30.24 28.28 31.64
3 PBS 29.49 27.73 32.20
3 PBS 30.00 28.10 34.04
3 PBS 29.29 28.12 31.52
6 PBS 29.09 28.60 32.11
6 PBS 29.54 30.31 32.67
6 PBS 30.36 28.39 31.42
6 PBS 30.49 29.19 33.13
6 PBS 30.16 29.38 32.26
9 PBS 30.03 28.28 31.89
9 PBS 31.26 28.23 31.64
9 PBS 30.18 28.31 33.25
9 PBS 29.29 28.31 33.21
9 PBS 31.46 31.07 34.32
3 P.a. 29.45 27.96 35.03
3 P.a. 29.52 27.63 31.81
3 P.a. 30.33 27.61 31.86
3 P.a. 30.99 28.03 32.84
3 P.a. 30.70 27.47 32.93
6 P.a. 29.73 28.16 33.47
6 P.a. 29.75 28.78 34.01
6 P.a. 29.51 28.43 32.22
6 P.a. 30.06 29.06 32.49
6 P.a. 29.58 29.10 33.87
9 P.a. 31.71 30.38 32.62
9 P.a. 29.93 29.17 32.98
9 P.a. 30.38 28.43 33.16
9 P.a. 30.10 30.33 33.04
9 P.a. 29.89 30.64 35.47
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Table C.9. linc-zgc:113057_2 RNA raw Cq values 
 
 
 
 
Time (hpi) P.a. or PBS injected Replicate #1 Cq Replicate #2 Cq Replicate #3 Cq
3 PBS 30.57 30.27 30.10
3 PBS 30.36 30.39 29.99
3 PBS 30.31 30.20 29.34
3 PBS 30.62 30.07 29.57
3 PBS 31.26 29.89 29.42
6 PBS 30.46 30.05 29.84
6 PBS 30.26 29.68 30.99
6 PBS 29.32 29.51 28.70
6 PBS 28.95 28.51 29.17
6 PBS 30.36 31.01 31.59
9 PBS 30.78 31.05 30.95
9 PBS 30.83 29.56 30.06
9 PBS 30.83 34.38 29.47
9 PBS 30.18 29.33 29.74
9 PBS 29.98 29.64 31.26
3 P.a. 27.27 27.05 26.96
3 P.a. 26.56 26.02 27.46
3 P.a. 26.97 26.27 27.16
3 P.a. 28.31 28.09 27.76
3 P.a. 28.04 27.70 26.13
6 P.a. 25.03 24.66 27.38
6 P.a. 25.15 24.99 28.86
6 P.a. 24.10 23.75 26.50
6 P.a. 24.73 24.22 28.21
6 P.a. 24.45 24.25 28.10
9 P.a. 24.89 25.64 26.96
9 P.a. 27.18 24.52 27.81
9 P.a. 24.76 26.85 28.56
9 P.a. 24.67 24.41 27.52
9 P.a. 24.67 24.39 28.67
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